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1.1 Summary 
In the context of new strategy development for the treatment of inflammatory bowel diseases, 
especially Crohn’s disease and ulcerative colitis, nanoparticular systems are considered as 
promising alternatives to the current treatments. Indeed, because of the accumulation of 
supramolecular objects in the epithelium of inflammatory bowel, a passive targeting could be 
achieved using drug carriers with the aim of increasing the efficacy and the safety for the 
patient. 
The objective of the present dissertation is to establish appropriate analytical methods to 
characterize nanocarriers and secondarily microcarriers. Two different types of formulations, 
namely the lipid nanoparticles (Lipidot®) and the poly(lactic-co-glycolic acid) (PLGA) micro- 
and nanoparticles were investigated. Studies were performed using budesonide and 
cyclosporine A as active pharmaceutical ingredients (API). In vitro drug release testing 
methods based on the derivative spectrophotometry using a fiber optic system were 
successfully developed for PLGA drug carriers whereas for the first time a solid phase 
extraction method for nanoparticles was designed and implemented to evaluate the carrying 
performances of the Lipidot®. Furthermore, the concept of automation was strongly 
considered during the selection step of analytical techniques with the following outlook: 
speed up the commercialization of nanopharmaceuticals. 
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 1.2 Zusammenfassung 
Im Rahmen der Entwicklung von neuen Strategien für die Behandlung von entzündlichen 
Darmerkrankungen, hauptsächlich Morbus Crohn und Colitis ulcerosa, werden 
Nanopartikularsysteme als vielversprechende Alternativen zu aktuellen Behandlungen 
betrachtet. Tatsächlich könnte, aufgrund einer Akkumulation von supramolekularen Partikeln 
im Epithelium von entzündlichen Geweben, ein „passive targeting“ mit Nanoträgern erreicht 
werden und somit zu einer erhöhten Wirksamkeit und größeren Sicherheit für den Patienten 
führen. 
Die vorliegende Dissertation beabsichtigt geeignete analytische Methoden zu entwickeln, um 
nanopartikulare/mikropartikulare Träger zu charakterisieren. Zwei verschiedene 
Formulierungen für den Transport von Wirkstoffen, nämlich die Lipid-Nanopartikel (Lipidot®) 
und die Poly(lactid-co-Glycolid) (PLGA) Mikro- und Nanopartikel wurden untersucht. Für die 
Experimente wurden Budesonid und Cyclosporine A ausgewählt. In vitro 
Freisetzungsmethoden wurden für PLGA-Wirkstoffträger mit einer Kombination aus 
Ableitungsspektrophotometrie und einem Fiberoptic Freisetzungssystem erfolgreich 
entwickelt. Außerdem, wurde erstmalig eine Festphasenextraktionsmethode für die 
Evaluierung der Beladung von Lipidot® für verkapselte Wirkstoffe entwickelt und 
angewendet. 
Darüber hinaus wurde besonderer Wert auf das Konzept der Automatisierung während der 
Methodenentwicklung gelegt, um die Kommerzialisierung von Nanopharmazeutika zu 
beschleunigen. 
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2.1 Background and Significance 
2.1.1 Inflammatory bowel diseases and conventional therapies 
The inflammatory bowel disease (IBD) actually consists of two major diseases of the 
digestive tract. However, these diseases are so pathologically close that they may not always 
be distinguished by the pathologist [1]. At the beginning of the 21st century, 1.4 million 
patients in the USA and 2.2 million in the Europe suffered from IBD [2]. The most frequent 
one, Crohn’s disease (CD), principally affects the ileum and colon and less frequently other 
locations in the gastrointestinal tract (mouth, esophagus, stomach or anus), whereas 
Ulcerative Colitis (UC) is more restricted to the rectum, though whole the colon may be 
involved [3]. The inflamed locations are continuous for UC but discontinuous for CD and 
histologically, the inflammation is often transmural for CD, while it is restricted to the mucosa 
for UC. Both are relapsing inflammatory chronic diseases. Extraintestinal manifestations may 
be observed (25 % of patients), such as for example arthritis, tendinitis, erythema nodosum, 
pancreatitis, myocarditis,… [4]. In the extreme case of the fulminant ulcerative colitis, 
frequent bloody stools going with bleeding and anemia can necessitate blood transfusions. 
This form of the disease can be accompanied by colonic dilatation, megacolon, abdominal 
tenderness, weight loss and high fever. The CD as well presents mild to fulminant forms and 
can be “fistulizing” [4]. IBD typically appears at the ages from 10 to 30 year old or later at 
around 60 year old [1]. Concerning the etiologies, many scientific studies were performed to 
identify the causes of the disease but the state of the knowledge is unfortunately still very 
lacking. To date, the main hypothesis relies on an auto-immune response in the mucosal 
tissue due to environmental and genetic factors [3]. Furthermore, even though the diagnostic 
tools improved over the last decades, the incidence of the disease increased and spread 
world-wide [5]. Concerning the current conventional treatments for IBD, 5-aminosalicylates 
like mesalazine (first-line therapy for UC), antibiotics like metronidazole, corticosteroids like 
prednisone or budesonide (BUD) and immunosuppressive agents like azathioprine or 
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 cyclosporine A (CSA) are used for both the inducing and the maintaining of remission phases 
[6]. For the refractory and fulminate forms, especially if no mucosal healing is reached, 
surgery is generally required [7]. For CD, 80 % of patients need an abdominal surgery and 
10 % a permanent stoma, whereas for UC, 10 % to 30 % required a colectomy [8]. Moreover, 
the conventional treatments are often not efficient enough and accompanied by adverse side 
effects. The corticosteroids used for short-term strategies often lead to mild side effects and 
more rarely to strong side effects like psychosis. The long-term treatments however induced 
stronger and irreversible adverse side effects (exogenous hypercortisolism) [9]. 
Immunosuppressive agents increase the risk of malignancy [10], as well as opportunistic 
infections. 5-aminosalicylates have been associated to hematological side effects [11]. 
More recently, biological therapies were developed for IBD to restore the balance between 
the pro- and the anti-inflammatory signals. These treatments can be based for instance on 
the blockage of the tumor necrosis factor using the following monoclonal antibodies (mAb): 
infliximab (Remicade®), adalimumab (Humira®), certolizumab pegol (Cimzia®) or golimumab 
(Simponi®). The natalizumab (Tysabri®), approved by the FDA in 2004, inhibits the integrines 
to prevent the leucocytes adhesion at the digestive tractus. However, a serious adverse side 
effect namely the progressive multifocal leukoencephalopathy limits the use of this treatment. 
More recently in 2013, another mAb based on the same mechanism but without that adverse 
side effect was approved for IBD: the vedolizumab (Entyvio®). Another pharmacological 
alternative achieved by the ustekinumab (Stelara®) involves the blockage of the interleukins 
12 and 23 required for the modulation of the immune system. Lastly, though recently 
developed, monoclonal antibodies therapies represent a very potent strategy for 
inflammatory bowel diseases [12]. 
To sum up, IBD can present severe forms and the etiologies are still poorly known. The 
current pharmacological treatments are often not efficient enough and lead to adverse side 
effects. This dissertation is actually to be placed in the context of new drug delivery 
strategies for inflammatory bowel diseases. 
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 2.1.2 New therapy strategies for inflammatory bowel disease 
C. Lautenschläger et al. [13] recently reviewed several alternatives to the current drug 
delivery strategies for IBD: 
- Designing inactive prodrugs that release in vivo active drugs 
- Embedding drugs into polysaccharide matrices 
- Controlled released drug delivery systems (Pressure-controlled and Osmotic-controlled 
Release Oral delivery Systems (OROS)) 
- Self Micro-Emulsifying Drug Delivery Systems (SMEDDS) to increase the bioavailability 
- Drug targeting using cell-based drug delivery systems (bacterial and eukaryote cells) or 
synthetic drug carriers (e.g. liposomes, micro- or nanoparticles) 
Drug targeting can be considered of a great relevancy for IBD considering the properties of 
the inflamed lining of the intestine. Indeed, for an experimental rat model colitis, an 
accumulation of entrapped drug in the inflamed regions was observed and depended of the 
carrier size [14]. Three pathways were actually described for the gastrointestinal uptake of 
nanoparticles: an uptake by a paracellular pathway or via the jejunal cells lining the intestinal 
mucosa (intracellular uptake) or else via the M-cells and Peyer’s patches [15]. In addition, an 
effect comparable to the so-called enhanced and permeation effect (EPR) is likely to occur in 
the inflamed locations of the gut. Initially described for tumor tissues, this effect is supposed 
to be caused by abnormal gaps between endothelial cells of the blood vessels of tumors [16]. 
The EPR-effect was thoroughly highlighted among the scientific publications during the last 
two decades but its relevance is more and more discussed nowadays [17, 18]. Even if the 
mechanisms of the accumulation of entrapped drug within the inflamed mucosal areas are 
not clearly identified, the concept of drug targeting using micro- or nanocarriers is still 
promising for IBD, as it was shown for example in the case of Polyethylene glycol (PEG)-
functionalized poly(lactic-co-glycolic acid) (PLGA)-microparticles [19]. 
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 This strategy was selected in the setting of this dissertation. The selected drug carriers were 
lipid nanoparticles (Lipidot®) and polymeric particulate systems, namely the PLGA-
microparticles and PLGA-nanoparticles. The carried APIs were two model drugs for the 
treatment of IBD: budesonide and cyclosporine A. In the case of budesonide (see Figure 1), 
a well-absorbed corticosteroid, the systemic bioavailability remains low because of a high 
first-pass hepatic metabolism. In addition, the risk of side effects is decreased with 
budesonide in comparison to prednisolone [20]. Moreover, opportunistic infections can be 
observed [4]. 
 
Figure 1: Budesonide 
Concerning cyclosporine A, a molecule naturally produced by the fungus Tolypocladium 
inflatum, the chemical structure consists of a cyclic polypeptide of eleven amino acids (see 
Figure 2). Because of its immunosuppressant pharmacological activity, cyclosporine A can 
be a cause of opportunistic infections for the patient. Moreover, nephrotoxicity, hypertension, 
headache, gingival hyperplasia, hyperkalaemia, paresthesias, and tremors can be 
observed [21]. Nevertheless, this API has a strong efficacity, in particular for severe UC [22]. 
 
Figure 2: Cyclosporine A 
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 2.1.3 Chemical characterization and performance tests for micro- and 
nanoparticulate drug carriers 
To achieve drug targeting, the following three conditions should be fulfilled for drug carriers: 
1. The initial free API amount is negligible compared to the entrapped API amount. 
2. The API is maintained entrapped in the carrier until the target is reached. 
3. The carrier releases the API at the target: at or in the tissue or in the cell. 
In this setting, the repartition of the API between the different compartments of the 
formulation should be quantitatively known after manufacturing and naturally should not 
significantly differ at the time of the administration (product stability). Consequently, 
performant analytical tools with reliable physical or mathematical separation methods are 
required to demonstrate the physical and chemical suitability of the formulation. 
Furthermore, the destiny of the API after administration requires monitoring. For this 
purpose, in vitro drug release testing (DRT) studies are generally performed in the case of 
conventional dosage forms. These tests are even considered as surrogate to clinical 
trials [23]. However, in the case of drug carriers, considering the three previously mentioned 
conditions, the concept of in vitro DRT appears completely different or even inappropriate as 
such. Indeed, though a sustained drug release at the targeted site is the main objective, the 
carrier should be on the contrary the most stable possible during the trip until the target so 
that a drug release does not prematurely occur. Actually, a concept for in vitro drug-load 
stability testing is currently missing but may be much more relevant for delivery strategies 
based on targeting than in vitro DRT only. Indeed, to re-create the mechanical and 
physicochemical environments crossed by the carrier until the target would be informational 
enough to optimize the formulation before further in vivo investigations. Unfortunately, no 
stress tests for micro- or nanoparticulate drug carriers have been noticed in the scientific 
literature precisely for the assessment of the drug-load stability of the system. However, the 
chemical and thermical stress tests usually carried out for the stability of conventional 
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 formulations can be adapted to the nano-/microcarriers. Besides, biorelevant media can be 
used to reproduce the stress conditions of the route of application until the target. 
Nowadays, many characterization tools could already be conceivable for the separation of 
API from particles or for in vitro drug release tests of drug carriers. Still, few of these 
techniques have intensively been investigated for drug carriers. The following parts review 
the state of the art for these techniques. 
 
2.1.3.1 Separation methods: State of the art for micro- and nanoparticles 
The quantification of free residual API still present after the manufacturing of micro- or 
nanoparticles or after release over an in vitro DRT often requires separations methods. A 
short overview of the relevant separation techniques is given below: 
The dialysis-based methods are strongly represented among these techniques. Dialysis is 
often used as a purification technique to remove free residual API or excess of excipients 
after manufacturing. The technique generally involves a dialysis tube filled with the 
formulation and placed in a large volume of aqueous medium. The medium is maintained 
under stirring from half a day to several days and may be refreshed at interval times to 
maintain the concentration gradient as strong as possible [24, 25] (see Figure 3). Such 
dialysis separation methods are often implemented to calculate the loading efficiency of the 
manufacturing process [26]. Nevertheless, a significant limitation of the technique is the time-
consuming permeation of the API through the membrane and the subsequent drug release 
that could occur during the process. In addition, a significant amount of nanoparticles has 
been documented to be lost by accumulation at the membrane [27]. Dialysis methods used 
for in vitro drug performance tests are detailled in paragraph 2.1.3.2. 
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Figure 3: Basic configuration for the dialysis separation techniques 
 
Further, a Spin Centrifugation–Dialysis (SCD) method was developed for the purification of 
nanoparticles. This preparative method consisted of a centrifugation step (1,000 g for 12 h) 
and a dialysis step (4-6 h). Although it would remain time consuming for an analytical 
method, the technique is inexpensive, easy, automatable and presented equivalent results to 
the reference technique of the study, namely the Tangential Flow Filtration (TFF), presented 
below [28]. 
Tangential Flow Filtration (TFF) or Cross-Flow Filtration (CFF) is a technique where the flow 
of a liquid containing the particles is parallel to the filter. The API to be separated from the 
particles permeates through the filter. CFF is usually used in R&D for the purification of 
nanoparticles or microparticles. The main advantage over dead-end filtration techniques is 
the decreased risk of clogging at the filter (see Figure 4). An electrostatic field can even be 
applied to optimize the filtration [29]. However, the deformability property of semi-solid 
nanoparticles is a limitation for the use of CFF. Lipid nanocapsules with initial size were 
reported to be detected in CFF filtrates for membranes with MWCO smaller than the particle 
diameter [27]. 
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Figure 4: Dead-End Filtration (left) versus Cross-Flow Filtration techniques (right) 
 
Giddings introduced in 1966 the concept of Field-Flow Fractionation (FFF) [30] which 
consists a separation of particles by differential migration. A field is applied perpendicularly to 
a narrow tube containing the pumped fluid with particles [31]. The tangential flow of the fluid 
is laminar and faster in the center of the tube. The active pharmaceutical ingredients, then 
the smallest particles, are eluted before the largest particles carried by the field to the so-
called “accumulation wall” (see Figure 5). 
 
Figure 5: Principle of the Field-Flow Fractionation (FFF) techniques 
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 The most common FFF techniques are the Symmetric and Asymmetric Flow FFF. In the 
case of Symmetric Flow Field-Flow Fractionation (SF4), the perpendicular field consists of a 
fluid flow crossing the tube, entering through an upper semi-permeable membrane and 
exiting through a lower semi-permeable membrane [32] (see Figure 6). 
 
Figure 6: Principle of the Symmetric Flow-Field-Flow Fractionation (SF4) technique 
 
For Asymmetric Flow FFF (AF4), the perpendicular field is caused by the tangential fluid 
itself exiting through a single bottom semi-permeable membrane [33] (see Figure 7). 
 
Figure 7: Principle of the Assymmetric Flow-Field-Flow Fractionation (AF4) technique 
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 Actually, a plethora of FFF techniques are available depending on the separation force field: 
Sedimentation FFF (SF3), Magnetic FFF (MgFFF), Medium Temperatur Asymmetric Flow-
FFF (MT AF4), Hollow-Fiber Flow FFF (HF5), Dielectrophoretic FFF (DEP-FFF), Split Flow 
Thin Cell Fractionation (SPLITT), Thermal FFF (ThFFF)... The latter is an example of FFF 
where a perpendicular temperature gradient is achieved warming up the upper wall and 
cooling down the bottom wall (see Figure 8). 
 
Figure 8: Principle of the Thermal Field-Flow Fractionation (ThFFF) technique 
 
A coupling of FFF to a physical detection technique can be achieved with many physical 
detectors. Although field flow fractionation offers decisive advantages for industry 
(automation, robustness…), very few methods are described in the field of the separation of 
free drug from nanoparticles. The technique is usually rather used for the separation of 
particles or polymers one to another. Nevertheless, the determination of the encapsulation 
efficiency of APIs has been already performed for liposomes using AF4 [34]. In addition, a 
method based on AF4 was successfully implemented not to monitor the in vitro drug release 
but the nanoparticle release from tablet dosage form [35]. 
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 As for FFF, Analytical Ultracentrifugation (ANUC or AU) can be used to physically 
characterize particles, polymers or macromolecules (size, distribution, molecular mass) [36]. 
The principle of the separation is based on the sedimentation velocity after centrifugation at a 
very high rotation speed (e.g. 100,000 rpm or 1,000,000 g). Usually, for chemical 
characterization, ultracentrifugation is used to precipitate particles and to quantify the free 
residual drug in the supernatant or the entrapped drug released after particle 
disintegration [37]. 
 
Concerning the techniques of filtration, the samples are generally eluted under low pressure 
through 0.1 to 1 µm-sized pore filters (microfiltration, MF) or 0.01 to 0.1 µm-sized pore filters 
(ultrafiltration, UF). The molecules (API), smaller than the pores, are eluted, whereas the 
particles, larger than the pores, are retained on the filter (see Figure 9). Though the simplicity 
of the technique, ultrafiltration presents disadvantages, especially the formation of cakes 
obstructing the filters [38, 39]. Moreover, the shape of soft nanoparticles may deform, as 
previously mentioned for CFF [27], and thus, nanoparticles or fragments may be partially co-
eluted in the stream with the API. 
 
Figure 9: Principle of the Ultra- and Microfiltration techniques 
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 Capillary Electrophoresis (CE) is a family of separation techniques based on the different 
electrophoretic motilities of electrically charged analytes subjected to an electro-osmotic flow 
(EOF) through a very narrow capillary (see Figure 10). The inner walls of the capillaries are 
often covered with ionizable silanol groups whose charge mainly depends on the pH of the 
buffer solution. Negatively charged silanoate groups tightly retain cations from the buffer 
forming a positively charged fixed layer. An outer mobile layer consisting of solvated cations 
can be set in motion when an electrical potential difference between the two ends of the 
capillary is applied. The generated flow of buffered solution corresponds to the electro-
osmotic flow (EOF). 
 
Figure 10: Principle of the Capillary Electrophoresis (CE) technique 
 
The mode of CE is selected according to the analytes to be separated: Capillary Zone 
Electrophoresis (CZE), Capillary Gel Electrophoresis (CGE), Isoelectric Focusing (IEF), 
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 Isotachophoresis (ITP), Micellar Electrokinetic Capillary Chromatography (MECC) (also 
reffered to as Micellar Electrokinetic Chromatography (MEKC)) and Microemulsion 
Electrokinetic Chromatography (MEEKC) are the main modes for capillary electrophoresis. 
In the case of neutral nanoparticles for instance, a micellar pseudostationary phase (MEKC 
mode) or a microemulsion pseudostationary phase (MEEKC mode) can be introduced into 
the capillary to enable the separation. Such techniques were successfully performed for the 
separation and quantification of the API from nanoparticles [40] or from liposomes [41]. 
 
Size-Exclusion Chromatography (SEC) involves separating large molecules, polymers or 
nanoparticles by elution through a column containing a stationary gel phase of porous beads. 
The smaller is a particle, the larger is the diffusion volume and the slower is the retention 
time (see Figure 11). The elution is solely size-dependent. SEC is also named Gel 
Permeation Chromatography (GPC) if the eluents are organic and Gel Filtration 
Chromatography (GFC) if they are aqueous [42]. 
 
Figure 11: Principle of the Size-Exclusion Chromatography (SEC) technique 
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 This separation technique can be coupled to many different types of detectors such as 
Ultraviolet detectors (UV), Fluorescence Detectors (FLD), Infrared detectors (IR), refractive 
index (RI), or Dynamic Light Scattering (DLS) for example. A coupling of SEC with the 
technique of Matrix-Assisted Laser Desorption Ionisation Time-Of-Flight Mass Spectrometry 
(MALDI-TOF MS) was successfully achieved to characterize the chemical composition and 
molecular weight of nanoparticles [43] and a coupling of SEC to HPLC for liposomes [44]. 
High Performance Size-Exclusion Chromatography (HPSEC) refers to SEC columns 
produced using materials that improve the speed and the resolution and allow higher 
pressure or temperature [45]. Coupling the SEC technique with a sample preparation method 
for the eluted nanoparticles is conceivable for instance to release and to quantify entrapped 
drug. 
 
Hydrodynamic Chromatography (HDC) presents the advantage to produce less shear forces 
on the particles compared to the SEC technique (see Figure 12). 
 
Figure 12: Principle of the Hydrodynamic Chromatography (HDC) technique. Medium circulating 
through capillaries (up) or between beads (down). 
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 This technique is suitable too for the characterization of the size, distribution and molecular 
mass of particles and polymers. The sample is injected into an open tube or a column 
containing beads. The flow between the interstices of the beads or the walls of the tube is 
maintained laminar with a parabolic profile so that an increasing velocity gradient of the 
streamlines occurs from the walls until the center. The retention time consequently 
decreases with the size or molecular mass of the analyte. The elution ranks are the same for 
both HDC and SEC [46]. 
 
Solid Phase Extraction (SPE) is another separation technique based on the same principle 
as liquid chromatography. It consists of cartridges containing a stationary phase in contact 
with a mobile phase dragging the analytes reversibly bounded from the stationary phase [47]. 
SPE is generally considered as a very powerful separation technique [48]. In addition, the 
implementation of the SPE technique to separate the API from the carrier has already been 
investigated for liposomes [49, 50]. In the context of this dissertation, methods based on solid 
phase extraction were developed for lipid nanoparticles (see Chapter III). 
 
Figure 13: Principle of the Solid Phase Extraction (SPE) technique as used in Chapter III 
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 Concurrently with physical separation methods, other techniques can be directly used for the 
determination of encapsulation efficiency. For instance, an 1H NMR-Spectroscopy method 
could be developed for liposomes with very accurate and robust results [51]. Furthermore, 
mathematical treatments based on derivative spectrophotometry can be used as “virtual” 
separation methods (see Chapter I and Chapter II). 
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 2.1.3.2 In vitro Drug Release Testing: State of the art for micro- and nanoparticles 
According to the USP, “drug product performance may be defined as the release of the 
active pharmaceutical ingredient (API) from the drug product dosage form, leading to 
systemic availability of the API necessary for achieving a desired therapeutic response.” [23]. 
For conventional dosage forms, in vitro drug release tests are carried out to assess the drug 
product performance and more precisely the “bioavailability” of the API. This term covers not 
only the amount of API reaching the blood stream but the kinetic of the phenomena as well. 
Two successive phases, actually starting concomitantly, the “disintegration” and the 
“dissolution”, follows after administration of the product and happens before the so-called 
ADME scheme (Absorption, Distribution, Metabolization and Excretion). The three main 
phases after oral administration are described in Figure 14. 
 
Figure 14: Successive stages following the oral administration of a drug 
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 The disintegration actually corresponds to the loss of consistency, shape and finally the total 
dismantlement of the dosage form. This biopharmaceutical phase is investigated using 
disintegration tests. As concerns the dissolution, the process refers to the passage from a 
crystal or an amorphous form of the API or an excipient-binded form toward a molecular form 
of the API in solution. The following absorption phase occurs only for the molecular form of 
the drug. This is the reason why the dissolution rate and completion determines the 
bioavailability of the drug. The solubility of the API is an essential factor with an effect on the 
dissolution. On the other hand, many API-independent factors, like the temperature, the pH 
and the medium, may have a strong influence on the dissolution. In vitro DRT is a powerful 
tool to investigate the drug performance since most of the influent factors can be assessed 
using standardized apparatus. However, the dissolution cannot directly predict the 
bioavailability or biologic activity. Theoretical models based on the Fick’s law have been 
developed to explain the dissolution mechanism. In 1897, Noyes and Whitney described the 
process using the following expression: dM/dt = DS/h(Cs-C), where dM/dt represents the 
mass rate of dissolution, M the amount of drug dissolved at the time point t, D the diffusion 
coefficient of the drug in the solution, S the surface area of the solid, h the thickness of the 
diffusion layer, Cs the saturation concentration of the drug and C the concentration in the bulk 
solution at the time point t [52]. If the concentration C is significantly less than Cs and 
considering S and h constant, then the dissolution rate is proportional to the saturation 
concentration, i.e. the dissolved concentration increased with a first order rate over time. 
These conditions, so-called sink conditions, occur at the beginning of the test before the 
surface area is changed and for concentrations less than 1/10th [53], 1/5th [53] or less than 
1/3rd [23] of the saturation concentration. More complex models were developed to consider 
more specifically the pharmaceutical form of the drug. Furthermore, in vitro DRT are perfectly 
suited during the formulation development to identify the “critical manufacturing attributes 
such as the impact of ingredient properties and the impact of the manufacturing process on 
drug product performance.” [23]. Indeed, the manufacturing of a pharmaceutical product with 
Introduction Background and Significance 
 
 
23 
 
 very reproducible and robust drug performances is required to guarantee the safety and 
efficiency to the patient. Initially, in vitro DRT was “developed as a quality control tool to 
ensure drug product quality and batch-to-batch consistency.” [23]. In the context of quality 
control, the simpler is the apparatus, the more robust and reproducible are the studies. 
Several devices are described in the American, European and Japan pharmacopoeias. The 
rotating basket apparatus (USP apparatus 1) and the rotating paddle apparatus (USP 
apparatus 2) [23] are simple devices which consist of a 1,000 mL vessel containing the 
dissolution medium and a vertical shaft equipped either with a basket containing the dosage 
form or a paddle (see Figure 15). The shape and the size as well as the position of the 
paddle or basket are precisely standardized. The temperature of the medium is normally 
maintained at 37 °C (± 1 °C), and for cutaneous or ophthalmic routes, at 32 °C (± 1 °C). 
Under current Good Manufacturing Practices (cGMPs), apparatus suitability tests should be 
performed [23]. Non compendial variations of these devices are commercially available, such 
as for instance the Palmieri basket designed for suppositories. The pharmacopoeias 
describe as well the reciprocating cylinder apparatus (apparatus 3 of the USP), also known 
as the Bio-Dis, the flow-through cell (USP apparatus 4), the paddle-over-disk (apparatus 5), 
the rotating cylinder (apparatus 6) and reciprocating holder (apparatus 7) apparatuses [23]. 
Since May 2014, the following apparatuses were recognized by the USP for the 
determination of the drug release rate for semi-solid dosage forms like creams, gels or 
ointments: the vertical diffusion cell apparatus, also called the Franz-diffusion cell, the 
immersion cell apparatus and an adapter for topical dosage forms to be placed into the USP 
apparatus 4 [23]. The flow-through cell apparatus was initially designed for poorly soluble 
solid dosage forms since an open loop configuration provides a continuous stream of fresh 
and drug-free medium directly pumped from a reservoir to allow the maintain of the sink 
conditions [54] (see Figure 16). 
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Figure 16: Apparatus 4 (Flow-through cell apparatus), according to the European 
Pharmacopoeia [55]. Top: schematic representation of an open loop circuit. New dissolution medium is 
continuously pumped into the cell so that sink conditions can be achieved. Down-left: large cell for 
tablets and capsules with tablet holder for large cell (bottom). Down-right: small cell for tablets and 
capsules with tablet holder for small cell (bottom). 
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 Concerning micro- and nanoparticulate systems, the concept of in vitro DRT does not 
basically differ from for conventional dosage forms if these systems are intended to increase 
the apparent solubility and bioavailability of poorly soluble drugs. For instance nanocrystals 
are drug crystals manufactured at a nanoscale to increase the specific surface area and 
accelerate the dissolution velocity [56]. However, nanoparticles can be produced as drug 
carrier for targeting purpose and even be injected directly into the blood stream, bypassing 
the biopharmaceutical phase. Since in vitro DRT is basically aimed to simulate the destiny of 
the API during the biopharmaceutical phase, the sense of such investigations for drug 
carriers becomes misleading. Instead, in vitro tests related to the destiny of the carriers in the 
blood circulation and microcirculation may become relevant. Tools such as microfluidic 
mimetic microvessels for example might become in the future of highest interest too [57]. 
Anyway, in the absence of suitable procedures, researchers still perform in vitro DRT as 
analytical tool for the optimization of the manufacturing and formulation process. 
As concern the drug performance assessment for nanoparticles or microparticles, most of 
the current methods do not involve compendial apparatus [58, 59]. The most documented 
procedures for in vitro DRT of nanoparticles involve a tightly sealed dialysis tube containing a 
volume of few milliliters sample. The MWCO of the selected dialysis membrane should be 
smaller than the particle size. The tube is placed into the dissolution medium maintained 
under stirring at 37 °C. The release samples are withdrawn over time and the medium may 
be refreshed to maintain the suitable conditions for the dialysis process [60, 61] (see in 
Figure 3 the configuration for the purification of nanoparticles). For that purpose, a 
continuous flow dialysis setup can even be achieved using pumps and the collected medium 
can be analyzed by HPLC [62]. Many configurations based on the dialysis principle have 
been documented for in vitro DRT. Floating dialysis tubes such as the Float-A-Lyzer® from 
SPECTRUM® LABORATORIES, INC are commercially available and successfully used for 
in vitro DRT [63] (see Figure 17). 
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Figure 17: The Float-a-Lyser
®
 device for in vitro DRT. 
 
Dialysis tubes may be placed as well in USP apparatus 2 (paddle) by mean of an 
adapter [64] (see Figure 18). 
 
Figure 18: USP apparatus 2 (paddle) in combination with dialysis tube. 
 
However, the sedimentation of nanoparticles may occur during the test since the samples 
are not agitated in the dialysis bag. Therefore, apparatuses like the USP apparatus 1 
(basket) modified replacing baskets by vertical glass cylinders ended at the bottom by a 
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 dialysis membrane may theoretically lead to more promising solutions [65, 66] (see Figure 
19). 
 
Figure 19: Modified USP apparatus 1 (basket) with vertical glass cylinders and dialysis membrane. 
 
In addition, the standardization of the procedure is an important issue that is why methods 
using compendial apparatus remain the most attractive. For example, a Dialysis Sac Adaptor 
(DSA) has been designed to be placed in a standard cell of the USP apparatus 4 (flow-
through cell) and has been tested for dispersed systems [67] (see Figure 20). 
 
Figure 20: USP apparatus 4 (flow-through cell) and Dialysis Sac Adaptor.  
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 Another technique using a compendial apparatus without any adaptation, since already 
equipped with a dialysis membrane, namely the Vertical Diffusion Cell (VDC), also called 
Franz-cell, has been reported for transdermal patches containing loaded nanoparticles [68]. 
The USP therefor points out the slope of the cumulative drug amount released plotted versus 
√t (where t = time) represents the rate of drug release [23]. 
 
Figure 21: Vertical Diffusion Cell (VDC), also named Franz cell [69]. A dialysis membrane can be 
placed between the upper dosage compartment and the lower receptor compartement. 
 
In any case, the main limitations of the dialysis-based methods are the tightness of the 
device, to be checked using dyes for instance, and the permeation kinetic through the 
membrane which may be too slow to enable DRT in some cases [70]. If the kinetic allows in 
vitro DRT, the apparent permeability constant of the API in the diffusion medium across the 
dialysis membrane should still be mathematically taken into account [71]. On the contrary, if 
the permeation kinetic limits the feasibility of dialysis methods, alternative techniques should 
be considered. For that matter, sampling-and-separation procedures may be required and 
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 would consist of a withdrawal of sample at interval time points followed by a separation 
method for quantification, as described previously. Another option would be the in situ 
monitoring of the drug release, for instance using a Drug Selective Electrode (DSE) [72] or a 
fiber optics device in combination with derivative spectrophotometry, as presented in Chapter 
I and II. 
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2.2 Aim of the Work 
The current transition for nanopharmaceuticals from R&D laboratories towards the 
pharmaceutical industry leads to many challenges, not only regulatory challenges but 
technical challenges too. Indeed, among the hurdles to overcome features the product 
characterization including quality control procedures that can be implemented in routine 
using reliable analytical methods. 
In the first place, many publications describe in vitro drug release tests for nanoparticles 
using not standardized and home-designed dissolution devices. An important objective for 
this dissertation work was hence to develop suitable methods using compendial apparatus. 
The selected strategy to achieve this goal was firstly, for each type formulation to be 
investigated, i.e. PLGA-particles and Lipidot®, to identify the simplest feasible technique, and 
secondly, to develop new methods based on the selected technique. Lastly, the optimization 
and the validation of the methods were performed until the best analytical performances are 
reached. 
For PLGA-particles, the use of fiber optics was quickly assessed as a feasible and promising 
solution to monitor in situ the drug release. However, it required the removing of 
interferences caused by the particles. That is the reason why mathematical separation 
methods based on derivative spectrophotometry were developed as well. Concerning the 
dissolution system, the apparatus 1 of the United State Pharmacopoeia (USP), namely the 
basket apparatus, was the simplest device suitable for both PLGA micro- and nanoparticles. 
By contrast, in situ monitoring using fiber optics was not feasible for lipid nanoparticles 
because of their optical transparence leading to the impossibility to discriminate entrapped 
API from free or released API. Thereby, most of the efforts done for the lipid nanoparticles 
actually focused on the identification of a reliable separation method that can be at a later 
stage automated. The separation of the free API from the entrapped API is not always trivial, 
notably for Lipidot®. Consequently, this dissertation was also aimed to select, evaluate, 
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 develop and validate the most suitable technique for lipid nanoparticles. After an arduous 
selection process, the Solid Phase Extraction technique appeared to be a promising way to 
characterize lipid nanoparticles. 
Finally, all established analytical methods were implemented to evaluate the performances of 
new nanoformulations and hence to allow their optimization in the spirit of a regulatory 
submission, in the context of the EuroNanoMed Project Delivering Nano-pharmaceuticals 
through Biological Barriers ‘BiBa’ (ERA-Net EuroNanoMed Project Number 13N11846). 
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I.1 ABSTRACT 
Automation takes an increasing place in all the fields of the pharmaceutical industry, such as 
manufacturing and quality control. In the field of in vitro dissolution testing, the fiber-optic 
system is often considered a promising tool because it allows in situ monitoring of the drug 
release without manual sampling, liquid transfer, and hence phase separation. This paper 
evaluates the use of fiber-optic in vitro dissolution testing and presents a technique to 
compensate for analytical interferences caused by excipients. 
 
 
 
I.2 INTRODUCTION 
To assess product performance and the quality of pharmaceuticals, in vitro dissolution tests 
are regularly carried out in the pharmaceutical industry. Over the past decades, these tests 
were more commonly performed manually. The tendency in industry is to reduce random 
error and optimize time and cost by automation. Dissolution testing is a composite 
procedure, with the bath as a sample preparation device, sampling and other transfer actions 
for liquids, filtration to obtain the portion dissolved, the chemical analysis (HPLC, 
spectrophotometry), and data processing at the end. All of the steps may introduce additional 
error, decreasing the precision of the final results. Automated systems may include 
automated sampling, processing of sample solutions, online quantification, and even 
cleaning. However, to reduce the number of steps to both accelerate the process and 
increase the precision of dissolution methods, alternative solutions may allow to omit the 
sample and filtration steps by measuring drug release directly in the vessels. Suitable probes 
that are connected by glass fiber to the spectrophotometer enable UV measurements at any 
selected time point. The goal of this paper is to review the suitability of fiber-optic systems for 
dissolution testing and to describe the limitations for use. An example of a fiber-optic system 
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with a “rod” probe is provided to expand the use. A method to compensate for the 
interferences by undissolved particles during in situ monitoring of the drug release is 
presented. 
 
 
 
I.3 DESCRIPTION OF THE SYSTEM USED FOR THE EXPERIMENTS 
The system comprised a UV–vis spectrophotometer (Varian Cary 50 Tablet) equipped with 
the Cary WinUV software and connected to an Agilent dissolution apparatus 708–DS by fiber 
optics. Among the different types of probes [73], the rod type was selected (Figure 22). The 
complete fiber-optic system is commercially available from Agilent Technologies. 
 
Figure 22: Temperature probe (left) with optic rod probe (right) (source: Agilent Technologies). 
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I.3.1 Advantages 
In addition to the general advantages provided by automated systems (e.g., sparing time, 
workforce), fiber-optic systems for in vitro dissolution offer following attractive features: 
(1) Drug dissolution is measured in situ. 
Firstly, the in vitro drug release studies become more accurate and precise as they 
allow observations of the phenomena as they occur in the vessel. No disturbances 
are introduced into the system by sampling. Sampling in the sense of dissolution 
kinetics implies the assumption that the aliquot withdrawn is representative of the 
dissolution process at a given time point and that the removal has no effect on either 
the aliquot or the entire system (i.e., its hydrodynamics). In situ monitoring does allow 
recording of the dissolution kinetics exactly at the site of action. As no sample solution 
is consumed, the sampling may be adapted to the grid needed to describe the 
kinetics adequately. The number of time points for analysis is not relevantly limited. 
 
(2) Measurements can be performed for small volumes. 
Possible interferences due to changes of the hydrodynamics are caused firstly by 
the relationship of the individual sample volume to the total volume and secondly by 
the total volume withdrawn as a function of sampling schedule. Fiber-optic 
measurements do not require sample removal. Therefore, the mechanical 
dissolution conditions remain unchanged throughout the experiment. The results are 
not biased by alterations due to volume-dependent hydrodynamics and secondary 
concentration changes by volume replacement with fresh medium. 
 
(3) Transfer of sample solutions is not required. 
As no transfer of sample solution is required, the time of analysis is significantly 
shorter, in particular in parallel experimental design: 
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n = 6 routine QC testing 
n = 12 f2 testing 
n = 24 USP stage testing 
In the case of multiple sampling, the timesaving effect is relevantly greater. 
 
(4) The use of tubing, syringes, and filters is not required. 
The risk of API adsorption at surfaces of tubing, syringes, or filters is hence omitted. 
As no consumables are needed for sample processing, their validation is not 
needed, not to forget the cost-saving effects. 
 
(5) There are no stability issues with sample solutions. 
Physical instabilities as an effect of evaporation may not occur. There is no 
temperature gradient as for instance between the vessel (37 °C) and the 
spectrophotometric cuvette (25 °C). Secondary physicochemical instabilities such as 
temperature-dependent precipitation are avoided. As there is no time delay due to 
storage of sample solutions, chemical stability of sample solutions is not an issue. 
 
(6) The chemical analyses are in real time. 
In particular, in analytical method development as well as dosage form 
development, dissolution results are available while the test is still running. The 
advantage is that operating the dissolution bath and performing the chemical 
analysis concomitantly allows stopping experiments at any given specification or 
expectation time point. This advantage is valid for any online analytical coupling 
such as flow-through cuvette or ion-selective electrode. It is given here for 
completeness. 
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I.3.2 Particular Caution 
In spite of the aforementioned advantages, using a fiber-optic system requires particular 
caution. 
(1) Resident rod probes can cause turbulences in the vessel. 
There are several reasons to leave the probes in the vessel for a time exceeding the 
pharmacopoeial specifications. Among others, these are to avoid entrapment of air 
in the optical path and crystallization of solids on surfaces. Recording of spectra also 
requires longer periods. However, the resident probes may bias the dissolution 
results. On a drug product, level validation is required. 
The interferences caused by the probes can be significantly reduced if the probes 
are raised between data recording from the pharmacopoeial sampling point to a rest 
point immediately below the medium surface. As an alternative, probes may be used 
with hydrodynamically optimized rods. Lu et al. [73] describe alternative probes, 
either in the shaft of the stirrer or those adapted to the curvature of the vessel. 
 
(2) Air bubbles adhere between the mirror and the glass fiber. 
Air bubbles may form by immersing the probes into the medium. Consequently, the 
probes should be maintained immersed all along the test. Moreover, without any 
efficient degassing, air bubbles may form at the probes during a test run. 
 
(3) Particles in suspension in the medium may form a thin layer on the probe. 
Over the dissolution test, a partial buildup tends to occur on the mirror of the probe 
in the case of media containing many particles such as excipient aggregates or even 
undissolved API. The phenomenon can be avoided by both orienting the opening of 
the probe toward the walls of the vessel or the shaft of the paddle or basket and 
raising the manifold between the measurements. 
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(4) Excipients may cause spectrophotometric interference. 
If the spectra of the API and the excipient overlap, the specificity is not given. 
Moreover, a simple subtraction of absorptions or the reference wavelength concept 
is generally inappropriate in the case where both the API and excipient 
concentrations increase over time. This may be solved by mathematical methods 
available to level out the interferences on the level of chemometry. For example, if 
the interfering compound has a maximal (or minimal) UV absorption within the 
absorption range of the API, then the drug substance can be quantified using the 
amplitude of the first derivative of the absorption spectrum at the zero crossing 
point [74]. Different derivative UV spectrophotometric methods are already 
described for interfering compounds with or without maximal, minimal, or constant 
absorption within the wavelength range of the API absorption [75, 76]. This paper 
focuses on the implementation of the derivative technique where the interfering 
compound has a constant UV absorption between two wavelengths within the 
absorption range of the API. Currently, this method is successfully used for in vitro 
dissolution tests (unpublished results). For interfering light scattering, derivative [77] 
and other corrective methods [78] are well described. 
 
I.3.3 Limitations 
The two main limitations encountered for the use of fiber-optic systems are: 
(1) Very turbid suspensions cannot be analyzed. 
In this case, the UV absorption of API is too weak compared with the total 
absorption of the suspension, thus quantification is impossible for very turbid 
suspensions. 
(2) Solutions with compounds producing interferences that cannot be 
mathematically removed. 
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I.4 DESCRIPTION AND EVALUATION OF A DERIVATIVE SPECTROPHOTOMETRIC TECHNIQUE 
I.4.1 Theory 
For a mixture containing a given excipient and a drug substance, the resulting absorption 
spectrum of the mixture (D0) is the sum of the absorption for both substances: 
 
Supposing that the UV absorption of the excipient is constant over a given wavelength range,
 , then the first derivative (D1) of the absorption spectrum of such an 
excipient will be close to zero within this range, further named “derivative range”: 
 
Consequently, the first derivative clears up the component brought by the drug substance by 
neutralization of the component brought by the excipient regardless of its concentration: 
 
According to the Beer-Lambert law: 
thus 
 
The API can be quantified directly using the amplitude of D1 within the derivative range: 
 
However, the sensitivity may be decreased after the derivative operation, which is why the 
area under the curve (AUC) may be computed between two wavelengths within the 
derivative range: 
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I.4.2 Method 
A stock solution of propranolol in purified water was first diluted to prepare the following 
dilutions set: 10, 20, 50, 80, 100, and 120 µg/mL. A first course of absorption measurements 
was carried out for all solutions. The set was then spiked with the powder of excipients so 
that all the suspensions of the set had an excipient concentration of 0.3 mg/mL. A second 
course of absorption measurements was carried out for all suspensions. Finally, suspensions 
from 0.1 to 1.0 mg/mL excipients were prepared using the previous propranolol solution 
(100 µg/mL) spiked with the powder of excipients. 
The baseline and blank were measured with purified water. The absorption spectra were 
acquired from 200 to 400 nm with a measurement interval of 0.50 nm and a measurement 
speed of 60 nm/min. For the “absorption method,” the amplitude of the UV absorption of the 
sample was extracted from the spectrum at 290 nm, whereas for the “derivative-based 
method,” the AUC of D1 was calculated from 290 nm and 317 nm. 
The calibration curves for the two quantification methods with and without excipients were 
calculated and compared. 
For the derivative-based method, the quantification response of the API spiked with 
excipients was correlated to the quantification response of the API in solution without 
excipients. 
Finally, the recoveries of the suspensions containing different amounts of excipients were 
computed by the derivative-based method to the standard solution containing 100 µg/mL 
propranolol. 
 
 
 
 
 
Experimental Part Chapter I: Fiber-Optics: Overcoming Matrix Interferences 
 
 
44 
 
I.4.3 Validation 
The UV absorption spectra and first derivative absorption spectra for propranolol with and 
without excipients are presented in Figure 23. 
 
Figure 23: UV absorption and first derivative absorption spectra for propranolol (PRO) in purified 
water with vs. without excipients (Excip.); (A) absorption spectrum without excipients; (B) absorption 
spectrum with excipients. Whereas APIs and excipients are released from the drug delivery device over 
the dissolution test, absorptions spectra shift upward from (A) to (B). (C) First derivative absorption 
spectrum without excipients; (D) first derivative absorption spectrum with excipients. 
 
 
The linearity of both methods was checked over the range of 10–120 µg/mL propranolol, and 
the determination coefficients (R2) as well as the limits of quantification (LOQ) are 
summarized in Table 1. The relative standard deviation (RSD) of the absorption method does 
not meet the specifications for R2 and LOQ. Hence, the principle was not applicable. On the 
contrary, the derivative-based method successfully fulfilled the linearity requirements in the 
presence of excipients. 
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Table 1: Linearity of the absorption and derivative-based methods with and without excipients. 
Method 
Excipient 
concentration 
(mg/mL) 
R2 
LOQ 
(µg/mL) 
Absorption 0.0 0.9998 0.07 
Absorption 0.3 n.a. n.a. 
Derivative 0.0 0.9999 0.05 
Derivative 0.3 0.9999 0.15 
 
The calibration curves of the propranolol quantification in purified water in the presence of 
excipients are presented for both methods in Figure 24. 
 
Figure 24: Linearity of the quantification methods for propranolol in purified water spiked with 
0.3 mg/mL excipients; absorption at 290 nm and area under the curve (AUC) of the first derivative (D1) of 
the absorption between 290 nm and 317 nm. 
 
 
The correlation of the quantification response with excipients to the quantification response 
without excipients has an R2 of 0.9998 to 120 µg/mL propranolol for the derivative-based 
method (Figure 25). This proves the successful elimination of the interferences caused by 
excipients (specificity). 
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Figure 25: Correlation curve between the quantification of propranolol in purified water without and 
with 0.3 mg/mL excipients using the area under the curve (AUC) of the first derivative (D1) of the 
absorption between 290 and 317 nm. 
 
Finally, the recoveries of the 100 µg/mL propranolol solution spiked with different excipient 
concentrations were 96–103 % for 0.1–0.7 mg/mL excipients and 94–103 % for 0.1–
1.0 mg/mL excipients. Hence, the accuracy of the derivative-based method is proven. 
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I.5 CONCLUSION 
Fiber-optic systems represent a suitable option to both increase the robustness of dissolution 
methods and facilitate the automation for in vitro drug release testing. The time-saving effect 
is remarkable. Though automation by fiber-optic systems may not be applicable to all 
pharmaceutical products, the range of use may be broadened by the level of data 
processing. The most important limitation effect by matrix interferences may be overcome by 
mathematical solutions, such as derivative spectrophotometric methods. The use is not 
limited to manufacturing industry but also includes R&D projects. 
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A new concept for in vitro drug release testing 
of micro- and nanoformulations using a fiber 
optic system and derivative spectrophotometry 
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II.2 ABSTRACT 
Aim of the study was to explore innovative approaches to in situ monitoring of drug release 
from micro- and nanoparticles, allowing abandoning complex and time consuming separation 
techniques. For this purpose, the combination of derivative spectrophotometry with fiber 
optics and a compendial basket in vitro dissolution apparatus was implemented. 
UV absorption spectra of poly(lactic-co-glycolic acid) (PLGA) microparticles and 
nanoparticles were obtained by an Agilent FiberOptic® system, allowing to mathematically 
compensate interferences with the released drugs. Quantification methods based on 
derivative spectrophotometry were first developed for microparticles loaded with either 
budesonide or cyclosporine A, and then extended to nanoparticles loaded with budesonide. 
These analytical methods were then applied to perform in vitro drug release tests. 
The results of the validation showed a satisfying linearity, limits of quantification, accuracy 
and repeatability for all selected quantification methods. Consequently, in vitro drug release 
tests could be performed and the results proved that the methods were discriminative to 
enable the selection of the most suitable formulations. 
This study demonstrates that the concept of derivative spectrophotometry in combination 
with fiber optics and some compendial dissolution apparatus can be used for in vitro drug 
release tests of micro- and nanocarriers without requiring cumbersome physical separation. 
 
Keywords: nanoparticles; microparticles; in vitro drug release testing; dissolution; fiber 
optics; derivative spectrophotometry; separation techniques; PLGA; budesonide; 
cyclosporine A 
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II.3 INTRODUCTION 
A recently made inventory of pharmaceutical products currently under clinical investigations 
or already approved for commercialization highlights the significant emergence of 
nanoproducts as a part of the future pharmaceutical market [79]. As the commercialization of 
nanoproducts requires evaluating the potential risk of such technologies, the Center for Drug 
Evaluation and Research (CDER) of the United States Food and Drug Administration 
recently pointed out the need of improvements of analytical methods for the characterization 
of nanoproducts [80]. At the forefront of the pharmaceutical product characterization, in vitro 
drug release studies play a key role in the establishment of in vitro-in vivo correlations 
(IVIVC) which represent a surrogate for clinical trials. The simplest methods using 
compendial apparatus are generally preferred, as long as they allow generating meaningful 
data for the investigated new formulation [81]. Furthermore, depending of the needs of the 
laboratory, the automation of the dissolution equipment is increasingly considered to optimize 
in vitro drug release studies in the field of pharmaceutical industry [82]. Besides economic 
aspects, an important concern is the optimization of the reproducibility, repeatability, 
precision and robustness of the analytical procedures, which requires as well the technically 
simplest methods possible. However, most of analytical procedures for in vitro drug release 
of nanoparticles introduce the issue of the separation which leads to rather complex 
methods, such for example dialysis [67, 83-85], ultrafiltration [86, 87] or biphasic dissolution 
media [88, 89]. As an attempt to work around the issue of separation, in situ monitoring using 
a fiber optics system in combination with compendial dissolution apparatus may be an 
innovative approach to develop automated methods for nanopharmaceuticals [90]. The 
feasibility of such a combination has already been tested for conventional dosage forms from 
the late 80’s, using a modified paddle apparatus (apparatus 2 of the United States 
Pharmacopoeia (USP)) with tablets containing felodipine [91]. However, the observation of 
interfering spectra is often considered as a limitation to the quantification of the active 
pharmaceutical ingredient (API) [92]. Yet, many methods based on derivative 
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spectrophotometry (DSP) have been successfully evaluated to selectively quantify the drug 
of interest in presence of interfering components, such as pharmaceutical preparations 
containing several APIs [93-98], containing interfering matrix excipients [99] or even 
containing light-scattering components [77]. Since particles in suspension generally scatter 
light [100], such DSP methods are worthy of being evaluated for micro- and 
nanopharmaceuticals. The goal of this investigation was to study the feasibility of combining: 
1) derivative spectrophotometry 2) fiber optics, and 3) some compendial in vitro dissolution 
apparatus, in order to monitor in situ the drug release from micro- and nanoparticulates 
systems. The interfering UV absorption spectra of poly(lactic-co-glycolic acid) (PLGA)-
microparticles (MPs) and PLGA-nanoparticles (NPs) were compared. In a previous work 
[101], it has been shown that the released API could be quantified selectively in presence of 
the API still entrapped inside the opaque polymeric matrix of the particles. Quantification 
methods based on DSP were hence developed and validated according to ICH guideline 
Q2A [102] for budesonide (BUD) spiked with placebo 5 µm MPs, then as well as for a second 
API, cyclosporine A (CSA) spiked with the same MPs. The concept was extended to 
budesonide spiked with placebo 150 nm NPs. However, another previous study performed 
using propranolol as model drug had already shown that the concept of DSP could not be 
extended for this nanoformulation if the API absorbs below 260 nm [101] which, however, 
applies for cyclosporine A. Finally, drug content determination and in vitro drug release tests 
were performed for BUD-loaded PLGA-MPs, CSA-loaded PLGA-MPs and Bud-loaded 
PLGA-NPs using the compendial basket apparatus (apparatus 1 of the USP) and a fiber 
optics system. 
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II.4 MATERIALS AND METHODS 
II.4.1 Materials 
The fiber optic system was provided by Agilent Technologies and was equipped with a 
UV/Vis spectrophotometer Cary 50 Tablet and a 1 mm probe type “rod”. The in vitro drug 
release tests were performed using a compendial basket apparatus (apparatus 1 of the USP) 
type 708-DS Dissolution Apparatus from Agilent Technologies equipped with 1 L-vessels and 
100 mesh-baskets. Rotating paddles (apparatus 2 of the USP) were used for the infinity 
tests. Cyclosporine A (CSA) and budesonide (BUD) were provided by RTC™. The placebo 
and API-loaded 5 µm spray-dried PLGA-microparticles were provided by the Helmholtz 
Institute of Saarbrücken as well as the placebo and BUD-loaded 150 nm PLGA-
nanoparticles. The acetonitrile hypergrade for LC-MS LiChrosolv® (ACN) was provided by 
Merck. The highly purified water – aqua valde purificata (AVP), was produced using a Milli-Q 
system type Q-POD® from Millipore. The simulated intestinal fluid pH 6.8 without pancreatin 
(SIF 6.8) and the phosphate buffer solution pH 3.0 (PB3) were prepared according to Ph. 
Eur. 7.5. The filters 0.45 µm GHP Acrodisc Glass Fiber were provided by Pall Life Sciences. 
The ultrasonic bath was a Sonorex Digital 10 P from Bandelin. 
 
II.4.2 Methods 
II.4.2.1 Comparison of the interferences caused by nanoparticles vs. 
microparticles 
An ultrasonic bath was used for 20 min at room temperature to disperse either the micro- or 
the nanoparticles from the placebo powders in the medium SIF 6.8. The weight concentration 
was 0.3 mg/mL of either MPs or NPs. The UV absorption spectra of the suspensions were 
measured with the fiber optics system between 200 and 350 nm using the medium SIF 6.8 
as baseline. 
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II.4.2.2 Development of derivative quantification methods 
The quantification methods were developed from calibration curves of API dilution sets 
spiked with nanoparticles (only in the case of BUD), with microparticles (for both BUD and 
CSA) and without nano- nor microparticles (BUD and CSA). More precisely, a stock 
suspension containing 0.60 mg/mL of placebo PLGA-microparticles was prepared dispersing 
the powder of MPs in SIF 6.8 using an ultrasonic bath for 20 min at RT (suspension M). 
Another stock suspension containing 0.50 mg/mL of placebo PLGA-nanoparticles was 
prepared in the same way (suspension N). A stock solution containing 2000 µg/mL 
cyclosporine A was prepared dissolving the drug in ACN (stock A). This stock solution was 
further diluted 1:10 using SIF 6.8 (solution A). Another stock solution containing 2000 µg/mL 
budesonide was prepared in the same way (stock B) and diluted as previously (solution B). 
Two dilution sets of drug (CSA and BUD) without micro- or nanoparticles were prepared 
diluting respectively the solutions A and B from 2 µg/mL to 16 µg/mL cyclosporine A and from 
2 µg/mL to 40 µg/mL budesonide using SIF 6.8. Two other dilution sets containing the same 
amount of drug (CSA and BUD) and 0.30 mg/mL PLGA-MPs were prepared as previously 
spiking the dilutions with the suspension M. A third dilution set of budesonide, containing 
0.25 mg/mL PLGA-NPs, was prepared as previously spiking the dilutions with the 
suspension N. According to this protocol, no dilutions contained more than 2 % ACN, v/v. 
The UV absorption spectra (D0) of the dilution sets were acquired from 200 nm to 350 nm 
with a scan rate of 60 nm/min using SIF 6.8 as blank and baseline. The first derivatives (D1) 
of the absorption spectra were calculated for each dilution. The second derivatives (D2) were 
calculated as well only for the dilutions containing budesonide spiked with nanoparticles and 
not spiked. A wavelength range was graphically selected so that the signal due to the 
interferences is removed without affecting the signal of the drugs (see the selected ranges in 
Table 2). Then the areas under the curves (AUC) of D1 and D2 within the selected 
wavelength range were calculated for each concentration in order to build the AUC-based 
calibration curves. The coefficients of determination (R²) and the limits of quantification 
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(LOQ) where calculated. The correlation between the quantification of budesonide without 
micro- and nanoparticles and the quantification of budesonide spiked with micro- and 
nanoparticles was checked using the Student’s t-test. 
Table 2: Quantification methods. BUD-MPs: budesonide-loaded microparticles; BUD-NPs: 
budesonide-loaded nanoparticles; CSA-MPs: cyclosporine A-loaded microparticles. AUC of D1: area 
under the curve of the first derivative absorption spectrum; AUC of D2: area under the curve of the 
second derivative absorption spectrum. The areas were used as quantification parameter, i.e. 
proportional to the drug concentration. 
Formulation BUD-MPs BUD-NPs CSA-MPs 
Parameter AUC of D1 AUC of D2 AUC of D1 
Wavelength (nm) 249 - 300 279 - 312 215 - 250 
 
II.4.2.3 Drug content determination 
The determination of the drug content was performed for three batches of each following 
formulation: budesonide-loaded PLGA-microparticles (BUD-MPs), cyclosporine A-loaded 
PLGA- microparticles (CSA-MPs) and budesonide-loaded PLGA-nanoparticles (BUD-NPs). 
Prior to the test, a solvent mixture containing 50 % (v/v) ACN and 50 % (v/v) PB3 was 
prepared (ACN:PB3). A given amount of particles was weight in an Erlenmeyer-flask (25 mg 
for BUD-MPs and for CSA-MPs and 20 mg for BUD-NPs) and a given volume of ACN:PB3 
was added (30 mL for BUD-MPs and for CSA-MPs and 10 mL for BUD-NPs). The samples 
were further agitated and placed 20 min in an ultrasonic bath. After filtration, the drugs were 
quantified using the DSP methods previously developed. The reference solutions for the 
quantification were prepared by dilution of the stock solutions stock A and stock B using 
ACN:PB3 until 124.1 µg/mL for CSA and 61.7 µg/mL for BUD. The baseline and blank were 
performed using ACN:PB3. 
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II.4.2.4 In vitro drug release tests 
The in vitro drug release tests were performed for three batches of each BUD-loaded 
formulation (repeatability of the manufacturing process) and one batch was investigated in 
triplicate (repeatability of the analytical method). Concerning the CSA-loaded formulation, the 
tests were performed for one batch in duplicate. Prior to the tests, the dissolution medium 
(SIF 6.8) was degassed using an ultrasonic bath for 15 min. The formulations were weighted 
directly in the baskets. The tests were performed using the drug release methods described 
in Table 3. 
Table 3: In vitro drug release methods 
Formulation BUD-MPs BUD-NPs CSA-MPs 
Apparatus Basket Basket Basket 
 100 mesh 100 mesh 100 mesh 
Amount 30 mg 120 mg 30 mg 
Dissolution medium SIF pH6.8 SIF pH6.8 SIF pH6.8 
Volume 500 mL 500 mL 500 mL 
Temperature 37 °C 37 °C 37 °C 
Rotation speed 75 rpm 75 rpm 75 rpm 
 
The UV absorption spectra were acquired at a scan rate of 60 nm/min from 240 nm to 330 
nm and from 200 nm to 260 nm for BUD and CSA formulations, respectively. A last test was 
finally carried out to force the release of the API by a strong physical stress on the 
formulation in order to reflect the cumulated release at the infinity time point. This infinity test 
was performed after 48 h using paddles rotating at 250 rpm for 1 h above the baskets 
removed and placed on the bottom of the vessels. The methods for the quantification of the 
APIs are summarized for each formulation in Table 2. The reference solutions for the 
quantification were prepared by dilution of the stock solutions stock A and stock B using SIF 
6.8 until 8.33 µg/mL and 5.0 µg/mL for CSA and BUD, respectively. The baseline and blank 
were performed using SIF 6.8. 
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II.5 RESULTS AND DISCUSSION 
II.5.1 Comparison of the interferences caused by placebo nanoparticles vs. 
microparticles 
According to the UV absorption spectra of the suspensions presented in Figure 27, both MPs 
and NPs could interfere with any APIs absorbing in the investigated wavelength range. The 
interferences caused by the microparticles formed a relative straight line above 215 nm. This 
signal could consequently be properly described above 215 nm by a zero- or first-degree 
polynomial function that could theoretically be removed by a first- or second-order derivative. 
However, the analytical response decreased with the order of the derivative that is why the 
first order was preferred when feasible. Concerning the nanoparticles, the shape of the 
spectrum was in relation to 1/λn, where λ is the wavelength and n the degree of the light 
scattering (between 2 and 4). An approximation of this signal between two wavelengths 
could be done with a first-degree polynomial function that could be removed by a second-
order derivative. 
 
Figure 27: UV-absorption spectra of PLGA-nanoparticles and PLGA-microparticles in SIF pH 6.8 
(Simulated Intestinal Fluid, without pancreatine), n = 3. 
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II.5.2 Saturation concentrations and sink conditions 
The dilution sets of BUD and CSA without particles were slightly turbid in the investigated 
concentration ranges. For higher concentrations, precipitates were observed suggesting that 
the saturation concentration in SIF 6.8 was reached above the investigated concentration. 
Indeed, the aqueous solubility of these APIs is very low: 40 µg/mL at 25 °C for BUD [103] 
and 42 µg/mL at room temperature for CSA [104]. Consequently, the amounts of the dosage 
form were adjusted so that the maximal concentration of released API was less than a third 
of the saturation concentration in order to maintain sink conditions as suggested in the USP 
[23]. 
 
II.5.3 Development of derivative quantification methods 
According to the spectra of the dilution sets of BUD and CSA spiked with PLGA-particles 
presented in Figure 28, the following derivative quantification methods could be selected for 
evaluation: area under the curve (AUC) of D1 between 249 and 300 nm (AUC-D1[249-300]) 
for budesonide spiked with microparticles (BUD-MPs), AUC-D2[279-312] for budesonide 
spiked with nanoparticles (BUD-NPs) and AUC-D1[215-250] for cyclosporine A spiked with 
microparticles (CSA-MPs). The results of the validation of the three selected methods 
presented in Table 4 confirm the suitability for quantifying the drug released from the 
formulations. However, an excellent correlation was established between the measured 
concentration of budesonide alone versus in presence of micro- as well as nanoparticles, 
respectively (Figure 29). 
Table 4: Validation of the derivative quantification methods and corresponding formulations 
Method AUC-D1[249-300] AUC-D2[279-312] AUC-D1[215-250] 
Formulation BUD-MPs BUD-NPs CSA-MPs 
PLGA Range (mg/mL) 0.00 – 0.30 0.00 – 0.25 0.00 – 0.30 
API Range (µg/mL) 0 – 20 0 – 40 0 – 16 
R² 0.9999 0.9991 1.0000 
LOQ (µg/mL) 0.23 0.41 0.50 
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Figure 29: Light blue curve: correlation between the AUC of D1[249-300]  for budesonide versus 
budesonide spiked with PLGA-microparticles. Unilateral Student’s t-test: p < 0.0005. Dark blue curve: 
correlation between the AUC of D2[279-312] for budesonide versus budesonide spiked with PLGA-
nanoparticles. Unilateral Student’s t-test: p < 0.005. According to result of the Student’s t-test, the value 
of the quantification parameters (i.e. AUC of D1[249-300] and AUC of D2[279-312]) do not significantly 
differ in presence or in absence of micro- and nanoparticles. As a consequence, in the selected ranges of 
concentrations, the drugs can be quantified regardless to the amount of micro- and nanoparticles. 
 
  
Experimental Part Chapter II: In vitro Drug Release for Micro- & Nanoparticles 
 
 
62 
 
II.5.4 Drug content determination 
The calculated mean drug contents, relative standard deviations (RSD), recovery ranges and 
recoveries to the expected values based on the weight are given for all the investigated 
formulations in the Table 5. 
Table 5: Results of the drug content determination for BUD-MPs, BUD-NPs and CSA-MPs. The 
theoretical drug content is related to the amount of drug introduced in the manufacturing process. The 
experimental drug content differs especially for nanoparticles because of a purification step aimed to 
remove unentrapped drug. 
Formulation Batch # 
Drug 
content 
(µg/mg) 
RSD 
(%) 
Recovery 
range 
(%) 
Recovery to the 
theoretical drug 
content (%) 
BUD-MPs Batch 1 (n = 3) 75.4 1.1 98 – 101 100.2 
Batch 2 (n = 1) 76.4 - - 101.4 
Batch 3 (n = 1) 80.1 - - 102.4 
Batches 1, 2 and 3 77.3 3.2 97 – 104 101.3 
BUD-NPs Batch 1 (n = 3) 28.6 2.8 97 – 103 68.6 
Batch 2 (n = 1) 28.1 - - 70.4 
Batch 3 (n = 1) 31.7 - - 81.9 
Batches 1, 2 and 3 29.5 6.7 95 – 108 73.6 
CSA-MPs Batch 1 (n = 3) 144.8 2.8 98 – 104 102.9 
Batch 2 (n = 1) 144.4 - - 102.6 
Batch 3 (n = 1) 152.0 - - 102.2 
Batches 1, 2 and 3 147.1 2.9 98 – 104 102.5 
 
The results showed a satisfying repeatability and accuracy both between batches 
(consistency of the manufacturing process) and within batches (performance of the drug 
content determination methods). However, the tests performed between batches were less 
repeatable for nanoparticles as for microparticles. Moreover, since the terminal step of the 
manufacturing process of the nanoparticles was a purification step, the recovery to the 
theoretical value of the drug content was not complete contrary to microparticles. 
Nevertheless, including the values of previous unpublished investigations performed on other 
batches of the same type of formulation, the recovery to the expectation was actually 
practically complete for nanoparticles as well. 
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II.5.5 In vitro drug release tests 
The drug release tests performed either in triplicate (budesonide) presented consistent 
trends with acceptable standard deviations (Figure 30), The tests performed using three 
batches showed a narrow standard deviation for BUD-microparticles but a larger deviations 
were observed for BUD-nanoparticles. As a consequence, the drug release tests were 
discrimitative enough to reveal a better manufacturing reproducibility for BUD-microparticles 
than for BUD-nanoparticles. In addition, the method could successfully discriminate the 
release kinetics of the micro- and nanoparticles and pinpoint the release mechanism. Indeed, 
a burst release (40 % release after 5 min) followed by a sustained release was observed for 
BUD-MPs whereas a much stronger burst release (60 % release after 5 min) was observed 
for BUD-NPs. Since the specific surface increases for smaller particles, the burst effect was 
stronger for the nanoparticles and suggested a large amount of drug adsorbed at the surface 
of the particles. The developed in vitro drug release methods successfully allowed the 
selection of the most suitable formulation for further development: BUD-MPs. 
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Figure 30: In vitro drug release profiles of the mean values and standard deviations for BUD-MPs 
and BUD-NPs. The last time point above 36 h corresponds to the infinity test. The drug release is 
expressed in percentage of the experimental drug content, as previously determined. Up: Repeatability 
between three batches (MP-1, MP-2 and MP-3 for BUD-MPs and NP-1, NP-2 and NP-3 for BUD-NPs). Down: 
Repeatability within batch (MP-1 in triplicate for BUD-MPs and NP-1 in triplicate for BUD-NPs). 
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The Figure 31 corresponds to the results for CSA-loaded PLGA-MPs. Contrary to the drug 
release profile obtained with BUD-nanoparticles, no significant burst effect was observed for 
this formulation containing microparticles, which remains in line with the previous 
observations. Kinetic differences based on the loaded drug were revealed by the drug 
release test, since cyclosporine A loaded microparticles presented a slower kinetic than 
budesonide loaded microparticles. According to these results, the CSA-MPs formulation 
represents the most hopeful candidate. 
 
Figure 31: In vitro drug release profiles of the mean values and standard deviations for one batch of 
CSA-MPs tested in duplicate. The last time point above 36 h corresponds to the infinity test. The drug 
release is expressed in percentage of the experimental drug content, as previously determined. 
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II.6 CONCLUSION 
This investigation on the combination of derivative spectrophotometry (DSP) with fiber optics 
and a compendial in vitro dissolution apparatus led to encouraging results. Indeed, 
quantification methods could be properly developed and validated for two model drugs, 
budesonide and cyclosporine A, and two particulate formulations, PLGA-nanoparticles and 
PLGA-microparticles. These methods were finally implemented to evaluate the in vitro drug 
release performances for the tested formulations. It could be shown that the release profiles 
for microparticles showed a much more pronounced retardation than for nanoparticles which 
showed a strong burst effect, suggesting that the latter might require some further 
optimization to reach suitable pharmaceutical properties. Concerning the repeatability of the 
manufacturing process, the results were in line with the expectations for such formulations in 
a development phase. Again, the repeatability was somewhat better for microparticles than 
for nanoparticles. 
Overall, this study demonstrates that the use of DSP to compensate for UV-absorption 
interferences caused by particles represents a valid alternative to manual sampling and 
physical separation methods. In this context, automation becomes more simple, time and 
costs are saved and the repeatability is improved. In principle, this concept can be extended 
to any kind of interferences, except for cases of very high turbidity or lack of mathematical 
solutions. Innovative drug delivery systems, such as micro- and nanoparticles, are thus not 
necessarily incompatible with compendial equipment and the regulatory challenges caused 
by the lack of analytical tools can be overcome. 
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III.1 ABSTRACT 
Purpose 
Contrary to physical characterization techniques for nanopharmaceuticals (shape, size and 
zeta-potential), the techniques to quantify the free and the entrapped drug remain very few 
and difficult to transpose in routine analytical laboratories. The application of Solid Phase 
Extraction (SPE) technique was investigated to overcome this challenge. 
Methods 
The separation of free and entrapped drug by SPE was quantitatively validated by High 
Performance Liquid Chromatography. The developed protocol was implemented to 
characterize cyclosporine A-loaded 120 nm-sized lipid nanoparticles (LNPs, Lipidot®) 
dispersed in aqueous buffer. The colloidal stability was assessed by Dynamic Light 
Scattering (DLS). 
Results 
Validation experiments demonstrated suitable linearity, repeatability, accuracy and specificity 
to quantify residual free, entrapped and total drug. For the investigated LNPs, the method 
revealed a very limited shelflife of the formulation when stored in an aqueous buffer at 5 °C 
and even more at elevated temperature. Nevertheless, the DLS measurements confirmed 
the stability of nanoparticles during Solid Phase Extraction (SPE) in a suitable concentration 
range. 
Conclusions 
Solid phase extraction (SPE), when successfully validated, represents a valuable tool for 
drug development and quality control purposes of lipid-based nanopharmaceuticals in an 
industrial environment. 
 
Keywords: Solid-phase extraction; Lipid nanoemulsion; Nanoparticles; Cyclosporine; 
Separation techniques   
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III.2 INTRODUCTION 
In the scientific literature, nanomedicines are often considered as a promising field that could 
offer many advantages over small molecules. Many nanoproducts are currently under clinical 
trial or have already been approved, such as Abraxane® (paclitaxel) Ferumoxytol® (iron 
supplement) or Amphotec® (amphotericin B) for instance. However, the path until the final 
status of “approved” appears to be harder as hoped [105]. The complexity of the 
nanotechnologies for human health is such that time consuming missteps are unfortunately 
very common [106]. In particular, suitable techniques for the physicochemical 
characterization of the product are of the highest importance to reliably interpret results of the 
next studies (in vivo tests, toxicity…). The shape, the size or the zeta-potential of 
nanoparticles are key parameters for which many techniques [107] are already available and 
thoroughly investigated. On the contrary, far fewer techniques can be implemented in routine 
to investigate the distribution of the Active Pharmaceutical Ingredients (API) within the 
different compartments of the nanoformulation, essentially to distinguish between the free 
and entrapped drug. Dialysis methods are common for this purpose but the interpretation of 
the results is often not so obvious [108]. Other separation techniques like Cross-Flow-
Filtration (CFF), Field-Flow Fractionation (FFF), Ultracentrifugation (UC), Ultrafiltration (UF), 
Capillary Electrophoresis (CE), Size Exclusion Chromatography (SEC) or Hydrodynamic 
Chromatography (HDC) have been proposed in the scientific literature [109]. Yet, simple and 
reliable methods, as required for quality control purposes, may not be generally feasible for 
any nanosystem. 
For the present study, the Solid Phase Extraction (SPE) technique was selected because it 
generally allows at a later stage the full automation of the analytical procedure and hence, a 
strong reproducibility. Moreover, SPE has already been successfully applied for liposomes 
[41, 110], suggesting that it may be suitable for lipid nanoparticles (LNP) as well. This paper 
deals with the development of SPE methods to quantify separately free and entrapped 
cyclosporine A in a patented nanocarrier: Lipidot® [111]. The colloidal stability of the 120 nm-
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sized LNPs passed through SPE-cartridges was verified by monitoring the particle size. The 
subsequent quantification of the API was performed by High Performance Liquid 
Chromatography (HPLC). The developed protocol as presented in Figure 32 consisted of a 
tripartite SPE-method including a Total Drug Content Determination method (TDCD), an 
Entrapped Drug Content Determination method (EDCD) and a Free Drug Content 
Determination method (FDCD). 
 
Figure 32: Simplified process description of the tripartite SPE-method 
 
After validation of the analytical procedure according to the ICH guideline Q2A [102], the 
protocol was implemented for the Lipidot® formulation. Finally, a 48 h-stress test at elevated 
temperature and stirring speed was performed to evaluate the stability of the 
nanoformulation. 
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III.3 MATERIALS AND METHODS 
III.3.1 Materials 
Suppocire NB™ was purchased from Gattefosse S.A. (Saint-Priest, France). Myrj™ S40 
(PEG 40 stearate, 1,980 Da) and Super Refined Soybean Oil were obtained from Croda 
Uniquema (Chocques, France). Lipoid® S75-3 (soybean lecithin at 69 % of 
phosphatidylcholine) provided by Lipoid GmbH (Ludwigshafen, Germany). All these 
excipients are pharmaceutical grade and used as received. Acetonitrile (ACN) and methanol 
(MeOH) were provided by LiChrosolv®, orthophosphoric acid 85 % by BDH Prolabo® and 
trifluoroacetic acid 99.9 % by EMD Millipore Corporation. All reagents were HPLC-grade. The 
cyclosporine A (CSA) was supplied by RTC Pharma. Highly purified water was produced 
using a Milli-Q® Gradient A10 from EMD Millipore Corporation. Lipidots are formulated using 
a VCX750 Ultrasonic processor from Sonics (Newtown, USA) equipped with a 3 mm-
diameter microtip. The balance was an AX205 from Mettler Toledo, the water bath was the 
type 19 of Julabo, the centrifuge was a Minispin from Eppendorf and the vortex was a 
Vortex-Genie 2 from Scientific Industries. The quantifications of the active pharmaceutical 
ingredient (API) were performed by high performance liquid chromatography (HPLC) using 
an Agilent 1100 Series system from Agilent Technologies with a degasser, oven and DAD-
detector. The HPLC-column was an XTerra® RP-18 (5 µm x 150 mm x 4.6 mm) from Waters. 
The separation of the drug from nanoparticles was carried out using a solid phase extraction 
(SPE) system from Supelco: Visiprep™ 12-Port Vacuum Manifolds. The SPE-cartridges 
Supelclean™ LC-18 SPE tube (1 mL, 60 Å pore size, 45 µm particle size) were provided by 
Supelco. The nanoparticle size experiments were performed using a Zetasizer Nano ZS from 
Malvern Instrument equipped with a 532 nm green laser source. The stress test was carried 
out using the Manual Diffusion Test System equipped with a 7 mL vertical diffusion cell 
provided by Hanson Research. 
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III.3.2 Lipidot® formulation 
The formulation of conventional Lipidot® has been previously described elsewhere [112, 
113]. The lipid phase was prepared by mixing lipophilic ingredients: wax, oil and Lipoid S75-3 
phospholipids, whereas the aqueous phase was composed of the hydrophilic PEG 
surfactants, MyrjS40, solubilized in 1X PBS aqueous buffer. After homogeneous melting at 
45 °C, both phases were crudely mixed and sonication cycles are performed during 5 min. 
The purification step was carried out overnight using dialysis (1X PBS, MWCO: 12 kDa, 
regenerated cellulose membrane, Spectra/Por®). Lipid nanoparticles (LNP) were finally 
formulated at a total concentration of lipids of 60 mg/mL and then filtered through a 0.22 µm 
cellulose Millipore membrane. For 120 nm-sized formulation, the lecithin/PEG surfactant 
weight ratio was 0.21 with a surfactant/core weight ratio of 0.43. Concerning the 
manufacturing of the CSA-loaded LNPs, an appropriate amount of CSA in absolute ethanol 
(45 µL of 63.7 mg/mL of CSA stock solution) was initially added to the oily phase, and then 
the solvent was evaporated under argon flow. The nanoparticles encapsulating CSA were 
then formulated as above described. CSA drug was initially loaded until a concentration of 
210 µg/mL and a total lipid concentration of 60 mg/mL. The blank nanoparticles were 
prepared without drug corresponded to the placebo formulation. 
 
III.3.3 Preparation of the SPE and HPLC mobile phases 
The solution of trifluoroacetic acid 0.5 % (v/v) (hereafter named TFA), was prepared diluting 
trifluoroacetic acid 99.9 % with highly purified water. The solution of ACN:H3PO4 5 mM 
(75:25; v/v) (hereafter named mobile phase A) and the solution of MeOH:H3PO4 5 mM 
(75:25; v/v) (Mobile phase B) were prepared mixing phosphoric acid 5 mM solution with 
respectively ACN and MeOH. The solution of phosphoric acid 5 mM was prepared by dilution 
of orthophosphoric acid 85 % with highly purified water. 
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III.3.4 Principle of the tripartite SPE-method for lipid nanoparticles 
The samples formerly stored at 5 °C were left without handling until equilibration at room 
temperature. As described in Table 6, media were successively introduced into the SPE-
cartridges for cleaning and equilibration prior to introduction of the samples of formulation. 
The nanoparticles were eluted in a first fraction (F1) adding TFA as eluent into the SPE-
cartridge. The free drug was eluted in a second fraction (F2) using ACN as a second eluent. 
The pressure in the vacuum chamber during the elution of LNPs (Step 3) was adjusted, 
resulting in a flow rate of 1 mL/min. 
The nanoparticles eluted in F1 could further be disintegrated to release entrapped drug. 
Briefly, the disintegration step consisted in mixing one volume of eluted nanoparticles with 
two volumes of ACN. The mixture was vortexed and centrifuged at 10,000 rpm for 10 min. 
The released drug in supernatant was quantified using a suitable HPLC method (EDCD 
method). 
The free drug eluted in F2 could be directly quantified by HPLC (FDCD method). 
The total drug content was determined for a sample without being passed through SPE but 
directly prepared as previously described in the disintegration step. The released entrapped 
drug and the free drug were quantified by HPLC (TDCD method). 
 
Table 6: SPE overall plan. ACN: Acetonitrile; TFA: Trifluoroacetic acid 0.5 % (v/v); Sample: 
Nanoformulation to be tested; NPs: nanoparticles; API: Active Pharmaceutical Ingredient; VF1: volumetric 
flask #1; VF2: volumetric flask #2. The volumetric flasks were made to the marks after elution using the 
same medium as used for elution. 
Step Medium Volume Pressure Fraction Container Function 
1 ACN ≈ 6 mL ≈ - 50 kPa 
F0 Waste 
Cleaning 
2 TFA ≈ 4 mL ≈ - 50 kPa Equilibration 
3 Sample 1 mL ≈ - 20 kPa 
F1 5 mL-VF1 Elution of NPs 
4 TFA ≈ 3 mL ≈ - 50 kPa 
5 ACN ≈ 4 mL ≈ - 50 kPa F2 5 mL-VF2 Elution of API 
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III.3.5 Assessment of the colloidal stability of Lipidot® following SPE protocol 
Size distribution of Lipidot® was investigated by dynamic light scattering (DLS) to monitor the 
colloidal integrity of the nanoparticles after being applied SPE method. Prior to SPE, the 
sample of placebo Lipidot® was diluted using TFA until 3, 6, 10, 15, 30 and 60 mg/mL LNPs. 
Each dilution of the set was further eluted by SPE as described in Table 6 until step 4. The 
fractions F1 were collected and the particle sizes were assessed using the Zetasizer Nano 
ZS. The solution of TFA was used as blank and placebo Lipidot® as negative control. Before 
measurement, samples were diluted in TFA to a dispersed phase weight fraction of 1 mg/mL 
in order to avoid multiple scattering effects. All samples were prepared in duplicate and 
analyzed in triplicate. The Z-average diameter (Size, nm) and polydispersity index (PdI) of 
the lipid nanoparticles were extracted from the second cumulant of the correlation function of 
the intensity distribution. Each result was the mean of three independent measurements 
performed at 25 °C, at a fixed angle of 173 °. 
 
III.3.6 SPE separation methods and validation by HPLC analysis 
The quantitative validation of the SPE method for the FDCD was performed for a set of 
placebo Lipidot® diluted with highly purified water solutions spiked with different proportions 
of cyclosporine A. A CSA stock solution was prepared in duplicate dissolving the powder of 
CSA in ACN until a concentration of 2842 µg/mL. A first CSA dilution set was then prepared 
by dilution of the stock solution using ACN until 284, 426, 710, 852, 1136, 1421 and 1705 
µg/mL CSA. The dilution set was further diluted with a dilution factor of 50 using highly 
purified water, so that the resulting dilution set contained 2 %, (v/v) ACN, i.e. less than the 
limit of 5 % above which LNPs disintegrate. The sample of placebo Lipidot® was added until 
a concentration of 9.6 mg/mL, i.e. until a LNP dilution factor of 4:25 (dilution set designated 
by “CSA + placebo Lipidot® for FDCD” in Table 7). In addition, another dilution set (“CSA for 
FDCD” in Table 7) was prepared without placebo Lipidot®. Each sample of both the dilution 
sets of CSA solutions and CSA-spiked placebo LNPs was investigated in triplicate by solid 
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phase extraction according to the validation plan presented in Figure 33 and using the SPE 
protocol previously described in Table 6. 
Table 7: Dilution sets prepared for the validation of the tripartite-SPE method. For the EDCD method, 
the data given in the table do not correspond to entrapped CSA because of the technical impossibility to 
spike drug inside nanoparticles. The value of the entrapped concentrations (from 0.00 to 2.27 µg/mL) were 
hence calculated from the concentration of CSA spiked in ACN (from 0.00 to 3.41 µg/mL), i.e. using a 
factor 1.5. For the TDCD method, the data were calculated as for the EDCD method. 
Dilution set CSA for FDCD 
Dilution label 0% 20% 30% 50% 60% 80% 100% 120% 
CSA (µg/mL) 0.00 5.68 8.53 14.21 17.05 22.74 28.42 34.10 
LNPs (mg/mL) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Dilution set CSA + placebo Lipidot® for FDCD 
Dilution label 0% 20% 30% 50% 60% 80% 100% 120% 
CSA (µg/mL) 0.00 5.68 8.53 14.21 17.05 22.74 28.42 34.10 
LNPs (mg/mL) 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 
Dilution set CSA + placebo Lipidot® for EDCD 
Dilution label 0% 20% 30% 50% 60% 80% 100% 120% 
CSA (µg/mL) 0.00 0.38 0.57 0.95 1.14 1.52 1.89 2.27 
LNPs (mg/mL) 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 
Dilution set CSA + placebo Lipidot® for TDCD 
Dilution label 0% 20% 30% 50% 60% 80% 100% 120% 
CSA (µg/mL) 0.00 0.38 0.57 0.95 1.14 1.52 1.89 2.27 
LNPs (mg/mL) 1.92 1.92 1.92 1.92 1.92 1.92 1.92 1.92 
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Figure 33: Validation plan for the tripartite SPE method. 
 
III.3.6.1 Validation FDCD method 
The FDCD method further consisted in maintaining the fractions F2 of eluted CSA in a water 
bath for 5 min at 37 °C. Aim of this step was to dissolve the precipitate formed by co-eluted 
excipients present in the extern phase of the Lipidot® formulation. The CSA was quantified by 
HPLC using the setups for FDCD (see in Table 7), compatible with the presence of co-eluted 
excipients. The specificity of the CSA separation was assessed from the fraction F1: the 
eluted LNPs were disintegrated as previously described and analyzed by HPLC to verify the 
absence of CSA in this fraction. The HPLC method used the setups for EDCD and TDCD 
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(see in Table 7), compatible with the presence of excipients released after disintegration of 
the nanoparticles. 
 
Table 8: Setups of the HPLC methods used for FDCD, EDCD and TDCD 
Parameters Setups for FDCD Setups for EDCD and TDCD 
Column XTerra®, RP-18 (5 µm x 150 mm x 4.6 mm) 
Elution mode Isocratic 
Mobile phase ACN:H3PO4 5 mM (75:25, v/v) MeOH:H3PO4 5 mM (75:25, v/v) 
Flow 1.0 mL/min 1.2 mL/min 
Wavelength detection 205 nm 
Temperature 55 °C 
Injection volume 30 µL 50 µL 
Run time 7 min 10 min 
Retention time 3.10 min (± 0.05 min) 6.55 min (± 0.10 min) 
 
III.3.6.2 Validation EDCD method 
Concerning the EDCD method, the validation focused on the step following the elution of 
LNPs in F1, since spiking placebo Lipidot® with entrapped CSA was not feasible. Placebo 
LNPs were diluted using highly purified water until a concentration of 9.6 mg/mL LNPs (i.e. 
LNP dilution factor 4:25) and were further investigated in triplicate according to the overall 
SPE-plan presented in Table 6, until step 4. Afterward, 0.5 mL of F1 were mixed with 1 mL of 
a dilution set of CSA in ACN containing 0.57, 0.85, 1.42, 1.71, 2.27, 2.84 and 3.41 µg/mL 
drug (dilution set designated by “CSA + placebo Lipidot® for EDCD” in Table 7). The resulting 
mixtures were shaken using the vortex to disintegrate the placebo LNPs and centrifuged for 
10 min at 10,000 rpm to precipitate the excipients and to only collect the CSA in supernatant 
solution. The HPLC setups used for EDCD are presented in Table 8. 
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III.3.6.3 Validation TDCD method 
The TDCD method was validated by diluting the placebo Lipidot® using TFA until equivalent 
concentration of LNP to Fractions F1 in EDCD methods (1.92 mg/mL LNPs). As used for the 
validation of the EDCD method, 0.5 mL of this latter diluted solution were mixed afterward 
with 1 mL of the same dilution set of CSA in ACN (dilution set designated by “CSA + placebo 
Lipidot® for TDCD” in Table 7). The mixtures were vortexed and centrifuged as previously 
described for the EDCD method and then analyzed using the same HPLC method (see 
Table 8). 
 
III.3.7 Implementation of the tripartite SPE method for a sample of cyclosporine A-
loaded Lipidot® formulation and stress test 
The SPE protocol was implemented for a sample of cyclosporine A-loaded 120 nm-sized 
Lipidot® as previously validated. After equilibration at room temperature and dilution of the 
sample (dilution factor 4:25 in highly purified water), the FDCD and the EDCD methods were 
implemented directly whereas for the TDCD method, a dilution in TFA with factor 1:5 was 
applied. All samples were prepared five times (n = 5). 
The protocol was implemented as well for the nanoformulation without the dilution step in 
highly purified water, namely 1 mL of Lipidot® product was placed in the SPE cartridge at 
step 3 (see Table 6) for the FDCD and EDCD methods and the product was directly diluted 
in TFA (dilution factor 1:5) for the TDCD method. 
Regarding the stress conditions, 7 mL of cyclosporine A-loaded Lipidot® formulation were 
placed in the acceptor compartment of the vertical diffusion cell (VDC) used without 
membrane as 1-compartment cell. The stress test was carried out for 48 h at 37 °C with a 
magnetic stirring of 500 rpm. The stressed product was analyzed as previously without the 
dilution step in highly purified water. 
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III.4 RESULTS AND DISCUSSION 
III.4.1 SPE technique applied to Lipidot® 
The developed protocol is based on the reverse-phase SPE concept, relying on the Van der 
Waals interactions between a hydrophobic analyte and a hydrophobic solid stationary phase 
(SPE-cartridge). This phenomenon leads to a stronger retention of the lipophilic analyte 
whereas the lipid nanoparticles are eluted faster by a hydrophilic mobile phase due to their 
outer hydrophilic PEG shell. The separation between the API and LNPs is further enhanced 
by the significant size difference of the two entities. Indeed, the stationary phase consists of 
beads containing pores smaller than the nanoparticle diameter but larger than the API as 
molecular entity. Based on these two mechanismes, PEG-shell lipid nanoparticles loaded 
with hydrophobic drugs or contrast agents can be eluted in a first step by using TFA as a 
hydrophilic mobile phase. In a second step, the retained drug can be eluted using ACN as a 
more lipophilic mobile phase. This technique is consequently suitable to separate and 
quantify either the remaining non-entrapped drug fraction after a given manufacturing 
process, to detect a leakage of drug during storage on the shelf, or even to monitor drug 
release during an in vitro performance test. Moreover, such separation of the API from the 
particles takes only few minutes whereas other techniques, like e.g. dialysis, may require 
several days, and thus might be of the same time scale as the expected drug release from 
the carrier. Contrary to polymer or inorganic nanoparticles, considering the metastable 
character of lipid nanoparticles when dispersed in aqueous buffer, techniques based on 
separation-precipitation cannot be applied. Methods requiring organic solvents would 
destabilize the interface of droplets resulting in a biphasic system (oil and water parts). 
Consequently, solid phase extraction turned out to be the most suitable separation method 
for lipid nanoparticles. 
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III.4.2 Assessment of the colloidal stability of Lipidot® following SPE protocol 
As colloidal nanoemulsions, Lipidot® are composed of lipid droplets surrounded by lecithin 
and coated with PEG surfactant with a particle size range from 50 to 120 nm to render 
colloidal stability, reported with a shelf-life in suspension over one year [112]. Because their 
interaction with the stationary phase materials could potentially affect the integrity of the 
nanoparticles it was necessary to confirm their colloidal stability after the SPE process to 
validate its use as a separation method. Such experiment was consequently performed using 
a Zetasizer Nano ZS after SPE process. It was firstly shown that the median size and 
Polydispersity Index (PdI) for different dilutions of LNPs in TFA (control dilutions) did not 
significantly differ one to another. This finding demonstrated that acid medium did not 
destabilize the LNPs. Secondly, obvious differences between the particle size of the LNPs 
eluted in TFA after SPE and the control-LNPs diluted in TFA were observed for the 
concentrations 3 mg/mL LNPs (no peak observed after SPE) and 6 mg/mL LNPs (delayed 
peak corresponding to larger particle sizes after SPE) (Figure 34 and Table 9). This suggests 
that nanoparticle concentration of 6 mg/mL and below should not be used. 
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Figure 34: Particle distribution for different concentrations of Lipidot
®
 samples before and after 
SPE. The control set of LNPs (top) was diluted until same concentration as the set of eluted LNPs through 
SPE (bottom). The size distribution remained constant for the whole control set (6, 10, 30 and 60 mg/mL). 
After SPE, the modal size remained not affected for the concentrations higher than 10 mg/mL but was 
shifted towards higher values at 6 mg/mL. 
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Table 9: Particle size (nm) and polydispersity index (PdI) for different concentrations of Lipidot
®
 
samples prepared by solid phase extraction (SPE) or not (Control) 
 Particle size (nm) PdI 
LNP concentration (mg/mL) Control SPE Control SPE 
3 n. a. 2849.0 n. a. 0.747 
6 123.3 169.3 0.125 0.129 
10 124.8 137.0 0.117 0.097 
15 n. a. 130.9 n. a. 0.141 
30 124.1 125.8 0.114 0.106 
60 124.4 123.8 0.125 0.106 
 
III.4.3 Validation of the tripartite SPE method 
The tripartite SPE method actually consists of preparative and analytical methods for the 
quantification of the total API (TDCD), the entrapped API (EDCD) and the free API (FDCD). 
The dilution set of CSA prepared without LNPs for the validation of the FDCD method was 
practically not turbid in the selected cyclosporine A concentration range. However, for 
concentrations greater than 35-40 µg/mL (before SPE), the turbidity increased, precipitates 
were observed and the validation test failed (RSD >> 5 %). The validation of FDCD 
succeeded using highly purified water as dilution medium until 34.10 µg/mL (see results in 
Figure 35 and in Table 10). The linearity and repeatability were slightly better in presence 
than in absence of Lipidot®, obviously reflecting the improved solubility of cyclosporine A by 
this formulation. 
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Figure 35: Linearity of the tripartite SPE method: measured HPLC area related to the CSA 
concentration for the TDCD, EDCD and FDCD methods. The given concentrations correspond to the 
samples after SPE. 
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Table 10: Validation of the tripartite SPE method: The given concentrations correspond to the samples 
prepared for HPLC analysis and should be multiplied by a factor 5 for FDCD and a factor 15 for EDCD and 
TDCD to calculate the concentration of the sample before preparation. Linearity performed with 20, 30, 60, 
100 and 120 % of the simulated free API concentration, 100 % corresponding to 5.684 µg/mL CSA for 
FDCD method and to 1.920 µg/mL CSA for both EDCD and TDCD methods. * Results for CSA without 
placebo Lipidot
®
; ** Results for placebo Lipidot
®
 spiked with CSA. 
Parameters FDCD* FDCD** EDCD** TDCD** 
Linearity     
 Range (µg/mL) 1.14 – 6.82 1.14 – 6.82 0.38 – 2.27 0.38 – 2.27 
 R² 0.9991 0.9991 0.9992 0.9997 
 LOQ (µg/mL) 0.41 0.17 0.26 0.16 
 LOD (µg/mL) 0.14 0.06 0.09 0.05 
 RSD (%) 3.97 1.71 2.56 1.67 
Repeatability (n = 3)     
 CV(%) at 20 % 5.59 2.13 0.93 1.33 
 CV(%) at 100 % 1.15 3.88 1.58 1.06 
 CV(%) at 120 % 1.95 1.68 1.02 1.56 
Accuracy (n = 3)     
 20 % 99.9 – 111.7 98.3 – 103.0 100.9 – 102.8 100.9 – 103.3 
 100 % 98.4 – 100.8 94.7 – 102.1 99.8 – 103.0 100.5 – 102.6 
 120 % 99.3 – 103.0 99.2 – 103.1 100.1 – 103.0 100.4 – 103.4 
Specificity No interfering peaks were observed at the retention time of the API 
 
For the EDCD and TDCD methods, the results of the validation were satisfying regardless of 
the very low selected concentrations. The areas corresponding to CSA in the chromatograms 
(see Figure 35 and Figure 36) were low for the EDCD and TDCD methods but still 
acceptable. All relevant peaks were separated with a sufficient resolution and peak 
symmetrie for a reproducible integration. Both methods presented very wide and high 
injection peaks attributed to excipients released after destruction of LNPs and immediately 
eluted by HPLC. However, further peaks were observed for TDCD but not for EDCD, 
suggesting that other excipients of the formulation were not eluted in the fraction F1 but 
instead co-eluted with CSA in the fraction F2. Additional peaks were actually observed for 
FDCD, but did not affect the quantitation of the drug related peaks.  
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III.4.4 Tripartite SPE method for a Lipidot® nanoformulation – Stress test 
A protocol of characterization based on the SPE technique was previously designed, 
developed and validated using placebo lipid nanoparticles. Its implementation was also 
performed using the loaded Lipidot® formulation. The tripartite SPE method was able to 
determine the concentrations of entrapped CSA (88.9 µg/mL), free CSA (67.5 µg/mL) and 
total CSA (163.8 µg/mL). Moreover, comparing the experimental total CSA concentration to 
the theoretical concentration (210.0 µg/mL), an encapsulation efficiency of the manufacturing 
process could be calculated (78 %) to highlight the loss of non-encapsulated drug removed 
over intensive dialysis during the manufacturing process. The protocol was further 
implemented using a diluted formulation of Lipidot® in order to assess the influence of a 
dilution on the release of CSA. The free CSA represented 41 % of the total concentration for 
the samples prepared without dilution, vs. 82 % for the diluted samples. The entrapped CSA 
was quantified as well and represented 54 % for undiluted sample vs. 11 % for diluted 
samples. The methods for free and entrapped CSA could successfully reveal a dilution-effect 
and were almost complementary. However, according to the results summarized in Table 11, 
the repeatabilities (coefficient of variation) were very satisfying for the total and free CSA 
content determination method but not optimal for the entrapped CSA. Consequently, when 
the complementarity between the three methods was not completely achieved, the 
unidentified amount should be to be related to the entrapped CSA (see Figure 37). As 
concern the results of the stress test at 37 °C and 500 rpm, a proportion of 68 % free CSA 
was observed after the stress test vs. 41 % free CSA without the test. The result suggested a 
sustained release potential for the Lipidot® formulations. All the results of the tests performed 
for CSA-loaded Lipidot® formulation are given in Table 11 and Figure 37. 
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Table 11: Total, entrapped and free CSA concentrations for the loaded Lipidot
®
 formulation. Dilution 
1:1: sample not diluted prior SPE separation; Dilution 4:25: sample diluted prior SPE separation; Dilution 
1:1 Stress test: sample stressed over 48 h, not diluted prior SPE. Experiments performed for n = 5. *: n = 
4. **: n = 3. CV: coefficient of variation. 
 
Dilution 1:1 
Mean (CV) 
Dilution 4:25 
Mean (CV) 
Dilution 1:1 
Stress test 
Mean (CV) 
Total CSA (µg/mL) 
 
163.8 (1.1 %) 155.5 (1.1 %) 178.8 (1.1 %) 
Entrapped CSA (µg/mL) 
% /Total CSA 
88.9 (8.5 %) 
54 
17.6 (15.3 %)** 
11 
39.0 (15.3 %) 
22 
Free CSA (µg/mL) 
% /Total CSA 
67.5 (6.3 %)* 
41 
127.1 (5.0 %) 
82 
121.5 (4.0 %) 
68 
Total - (Entrapped + Free) (µg/mL) 
% /Total CSA 
7.4 
5 
10.8 
7 
18.3 
10 
 
 
Figure 37: Total, entrapped and free CSA concentrations for the loaded Lipidot
®
 formulation. Top-
left: Dilution 1:1 (sample not diluted prior SPE separation). Bottom-left: Dilution 4:25 (sample diluted prior 
SPE separation). Top-right: Dilution 1:1 Stress test (sample stressed over 48 h, not diluted prior SPE). 
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III.5 CONCLUSION 
An accurate, repeatable, fast and automatable method based on SPE wasdeveloped for the 
separation and quantification of non-entrapped and entrapped cyclosporine A in the lipid 
nanoformulation Lipidot®. The results obtained by DLS have shown that nanoparticles were 
actually eluted in a first fraction. Furthermore, the validation of the technique by HPLC 
resulted in very satisfying results revealing an excellent analytical performance of the method 
and usability for quality control purposes. At this stage of product developement, the SPE 
technique clearly demonstrated the complexity of the Lipidot® formulation as well as 
necessary further improvements towards a pharmaceutical product. Besides testing drug 
release and leakage during storage, respectively, the technique would also allow to quantify 
the amount of API removed during the purification step of the manufacturing process and 
thus the encapsulation rate and efficacy. Apart from the considerations related to the specific 
formulation, which served as an example for the study, the concept of SPE presents itself as 
very promising tool for drug development and quality control purposes of lipid-based 
nanopharmaceuticals in an industrial environment. 
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As previously mentioned, inflammatory bowel disease concerns millions people in the world, 
the clinical consequences can be very severe, the etiology remains poorly known and the 
current treatments are often either not sufficient enough or accompanied with strong adverse 
side effects. This is the reason why safe and efficient new treatments are needed. Passive 
targeting using nanocarriers represents exactly the strategy of interest. In this context, 
analytical tools to assess the manufacturing process of candidate formulations and their in 
vitro drug release performances are desired. 
In the scientific literature, methods are available for in vitro drug release testing but most are 
based on home-designed dissolution devices, typically including dialysis systems, and are 
generally not suitable to achieve quality control tests required for regulatory submissions. 
Moreover, in the particular case of lipid nanoparticles and because of its metastable 
character, no reliable techniques are available for the assessment of the formulation drug 
load. The present dissertation attempted to provide analytical tools based on standardized 
compendial apparatuses and that presents suitable analytical performances with the 
possibility of automation. 
Concerning the polymeric drug carriers, namely the PLGA-nanoparticles and PLGA-
microparticles, a drug content determination method and in vitro drug release testing 
methods were developed. The drug content determination method was based on the use of a 
solvent to release the whole amount of API from the polymeric matrix. The validation 
concluded to a narrow accuracy (98 – 101 % for budesonide microparticles, 97 – 103 % for 
budesonide nanoparticles and 98 – 104 % for cyclosporine A microparticles). In vitro drug 
release methods for polymeric micro- and nanoparticles could be further developed using the 
combination “fiber-optic system – derivative spectrophotometry – compendial basket 
dissolution apparatus”. The fiber-optic system presented the advantage to monitor in situ the 
drug release so that sampling, filtration and sample preparation were not required anymore. 
The derivative spectrophotometry was necessary to correct the interferences produced by 
the nano- or microparticles and to quantify the released drug. The basket apparatus was the 
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simplest compendial apparatus for the in vitro assessment of the performances for these 
formulations. As a result, robust methods completely automatable were performed for all 
three polymeric formulations. The resulting drug release profiles showed a strong burst effect 
for the nanoparticles but a moderate burst release followed by a sustained release for the 
microparticles. To sum up, the developed analytical methods revealed that polymeric 
microparticles of PLGA were suitable as such for pharmaceutical development but 
nanoparticles require further optimization, for instance by coating. In vitro DRT remains in 
this context the most suitable tool to assess the performances of new formulations. 
As concern the lipid drug carriers, i.e. the Lipidot®, methods to determine the total drug 
content and to separate free residual or released drug from nanoparticles were successfully 
established. The total drug content determination method (TDCD) was based on the use of a 
solvent mixture to disintegrate the nanoparticles and to release the whole amount of API 
trapped in the carrier. This method was aimed to be used in combination with a separation 
technique: the solid phase extraction (SPE). The SPE leaded to a first fraction containing 
only free drug (free drug content determination method: FDCD) and a second fraction 
containing only entrapped drug in nanoparticles. Isolated lipid nanoparticles can further be 
disintegrated using the same method to release and to quantify specifically the entrapped 
drug (entrapped drug content determination method: EDCD). This “tripartite-method” was 
favorably validated and presented an accuracy of 95 – 102 % for the FDCD method and 100 
– 103 % for both the EDCD and TDCD methods. As for the in vitro drug release method 
developed for polymeric drug carriers, the SPE method was aimed to be at a later stage 
completely automated for routine analysis. The tripartite-SPE-method was implemented for a 
sample of Lipidot® before and after a stress-test and after a dilution step. According to the 
results, a large amount of drug was either already released before analysis or not entrapped 
after manufacturing (42 %). Moreover, after dilution of the formulation, a much larger amount 
of free drug was unexpectedly observed (83 %). Further investigations are required to 
confirm this dilution-induced release and to identify the causes of this effect. However, the 
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formulation was stable enough to maintain entrapped a significant amount of API during a 
48 h-lasting stress-test. Indeed, 42 % of entrapped drug remained entrapped after the test. 
As a conclusion, a powerful analytical tool for the characterization of Lipidot® was established 
and is now available for the optimization of the manufacturing process (entrapment 
efficiency), of the purification process and of the storage conditions. This characterization 
method can be used to investigate the hypothetical dilution-induced drug release and more 
generally as sample preparation for in vitro drug release tests or drug-load stability tests. The 
preliminary studies performed for a loaded formulation already revealed that Lipidot® present 
promising release properties, namely the appropriate balance between stability and release 
required for any drug carrier system. 
Finally, the present dissertation enabled the use of a standard compendial dissolution 
apparatus for the assessment of in vitro performances of nanopharmaceuticals. In addition, 
this work provided an original solution for lipid nanoparticles for which no reliable method 
was available to date to quantify selectively free or released drug and entrapped drug. The 
investigated techniques showed adequate analytical performance for quality control 
purposes in an efficient industrial context, including the potential to be automated at a later 
stage. The optimization of the investigated nanoformulations was highlighted by the 
developed analytical tools to be necessary for the pharmaceutical development of drug 
nanocarrier platforms. At a final stage, the commercialization of such therapeutic platforms 
may be a promising alternative treatment for diseases, such as the inflammatory bowel 
disease. 
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λ Wavelength 
1H-NMR Proton Nuclear Magnetic Resonance 
ACN Acetonitrile 
ADME Absorption, Distribution, Metabolization and Excretion 
AF4 Asymmetric Flow Field-Flow Fractionation 
ANUC Analytical Ultracentrifugation 
API Active pharmaceutical ingredient 
AU Analytical Ultracentrifugation 
AUC Area under the curve 
AVP Aqua valde purificata (Highly purified water) 
BUD Budesonide 
CD Crohn Disease 
CE Capillary Electrophoresis 
CFF Cross-Flow-Filtration 
cGMP current Good Manufacturing Practices 
CSA Cyclosporine A 
CV Coefficient of Variation 
CZE Capillary Zone Electrophoresis 
D0 Zero-order derivative 
D1 First-order derivative 
D2 Second-order derivative 
List of Abbreviations  
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DAD Diode Array Detector 
DLS Dynamic Light Scattering 
DRT Drug Release Testing 
DSA Dialysis Sac Adaptor 
DSE Drug Selective Electrode 
DSP Derivative Spectrophotometry 
EDCD Entrapped Drug Content Determination 
EPR Enhanced Permeation and Retention 
EOF Electro-Osmotic Flow 
F0 Fraction 0 
F1 Fraction 1 
F120 Formulation containing 120 nm-sized lipid nanoparticles 
f2 Similarity Factor 
F2 Fraction 2 
F50 Formulation containing 50 nm-sized lipid nanoparticles 
FDA Food and Drug Administration 
FDCD Free Drug Content Determination 
FFF Field-Flow Fractionation 
FLD Fluorescence Detector 
GFC Gel Filtration Chromatography 
GPC Gel Permeation Chromatography 
List of Abbreviations  
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H3PO4 5 mM Phosphoric acid solution 5 mM 
HDC Hydrodynamic Chromatography 
HF5 Hollow-Fiber Flow Field-Flow Fractionation 
HPLC High Performance Liquid Chromatographie 
HPSEC High Performance Size-Exclusion Chromatography 
IBD Inflammatory Bowel Diseases 
IR Infrared 
IVIVC In vitro-in vivo correlation 
LNP Lipid Nanoparticle 
LOD Limit of Detection 
LOQ Limit of Quantification 
mAb monoclonal Antibody 
MALDI Matrix-Assisted Laser Desorption Ionisation 
MEKC Micellar Electrokinetic Chromatography 
MEEKC Microemulsion Electrokinetic Chromatography 
MeOH Methanol 
MF Microfiltration 
MP Microparticle 
MS Mass Spectrometry 
MWCO Molecular Weight Cut-Off 
n. a. Not available/not applicable 
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NP Nanoparticle 
OROS Osmotic-controlled Release Oral delivery System 
PB3 Phosphate buffer pH 3.0 
PBS Phosphate Buffered Saline 
PdI Polydispersity Index 
PEG Polyethylene Glycol 
Ph. Eur. European Pharmacopoeia 
PLGA Poly(lactic-co-glycolic acid) 
PRO Propranolol 
QC Quality Control 
R&D Research and Development 
R² Determination coefficient 
RI Refractive Index 
RP Reverse Phase 
rpm Revolutions per minute 
RSD Relative Standard Deviation 
RT Room Temperature 
SCD Spin Centrifugation-Dialysis 
SEC Size Exclusion Chromatography 
SF3 Sedimentation Field-Flow Fractionation 
SF4 Symmetric Flow Field-Flow Fractionation 
List of Abbreviations  
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SIF 6.8 Simulated intestinal fluid pH 6.8 without pancreatin 
SMEDDS Self-Micro-Emulsifying Drug Delivery System 
SPE Solid Phase Extraction 
SPLITT Split Flow Thin Cell Fractionation 
TDCD Total Drug Content Determination 
TFA Trifluoroacetic acid 0.5 % (v/v) 
TFF Tangential-Flow-Filtration 
ThFFF Thermal Field-Flow Fractionation 
TOF Time-Of-Flight 
UC Ultracentrifugation 
UF Ultrafiltration 
USP United State Pharmacopoeia 
UV Ultraviolet 
VDC Vertical Diffusion Cell (Franz cell) 
VF1 Volumetric flask for the elution of the fraction F1 
VF2 Volumetric flask for the elution of the fraction F2 
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